US Pat. No. 10,556,959

ANTI-CD39 ANTIBODIES AND USES THEREOF

Xencor, Inc., Monrovia, ...

1. An isolated antibody that binds to CD39, wherein the antibody comprises:(a) a heavy chain variable (VH) region comprising a VH CDR1 having SEQ ID NO:155, a VH CDR2 having SEQ ID NO:160, and a VH CDR3 having SEQ ID NO:165; and/or
(b) a light chain variable (VL) region comprising a VL CDR1 having SEQ ID NO:169, a VL CDR2 having SEQ ID NO:173, and a VL CDR3 having SEQ ID NO:175.
US Pat. No. 10,556,960

METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DISORDERS IN PATIENTS WITH ELEVATED LEVELS OF TLR4 LIGANDS AND OTHER BIOMARKERS

NovImmune SA, Geneva (CH...

1. A method of alleviating a symptom in a subject having a disorder associated with excessive aberrant TLR4 signaling or elevated TLR4 ligand expression or activity, the method comprising:a) identifying a subject having an elevated level of expression of citrullinated fibrinogen and citrullinated histone 2b compared to a control level of expression; and
b) administering an anti-TLR4 antibody or an immunologically active fragment thereof that binds and neutralizes TLR4, in an amount sufficient to alleviate the symptom of the disorder.
US Pat. No. 10,557,216

AUTOMATED INSTRUMENTATION FOR PRODUCTION OF T-CELL RECEPTOR PEPTIDE LIBRARIES

Inscripta, Inc., Boulder...

1. An automated method of creating a cell library expressing putative TCR binding antigens using instrumentation, the method comprising:providing a population of cells;
processing the population of cells using an instrument for multiplexed nuclease-directed genome editing using introduced nucleic acids and a nucleic acid-directed nuclease to create cells comprising nucleic acids that encode putative TCR binding antigens configured to be displayed on a surface of the cells;
incubating the processed cells to facilitate nucleic acid editing in the cells, wherein the editing provides nucleic acids that encode the putative TCR binding antigens in the cells; and
allowing the cells to express and display the putative TCR binding antigens on the surface of the cells.
US Pat. No. 10,556,961

ANTI-CD38 ANTIBODIES FOR TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA

JANSSEN BIOTECH, INC., H...

1. A method of treating a subject having relapsed or refractory acute lymphoblastic leukemia (ALL), comprising administering to the subject in need thereof an anti-CD38 antibody comprising heavy chain complementarity determining regions (HCDR) 1 (HCDR1), 2 (HCDR2) and 3 (HCDR3) sequences of SEQ ID NOs: 6, 7 and 8, respectively, and light chain complementarity determining regions (LCDR) 1 (LCDR1), 2 (LCDR2) and 3 (LCDR3) sequences of SEQ ID NOs: 9, 10 and 11, respectively, in combination with vincristine.
US Pat. No. 10,557,217

FIBERS WITH MODIFIED CROSS SECTIONAL PROFILE

THE EUCLID CHEMICAL COMPA...

1. A method for making a fiber reinforcement with variations in transverse cross section, comprising:forming a fiber having a surface, a core, and a first transverse cross section, said fiber comprising axially aligned polymeric material having a melting point temperature, said polymeric material comprising one or more of polyethylene, polypropylene, nylon, polyester, and polyvinylidene difluoride;
exposing said fiber to a heat treatment temperature between 800° C. and 3,000° C. for between 0.015 seconds and 0.5 seconds, such that at least a portion of the polymeric material at or near the surface of said fiber is at or above the melting point temperature and the polymeric material at or near the core is below the melting point temperature, wherein said polymeric material above the melting point temperature becomes unaligned, forming at least one fiber area having a second transverse cross section greater than said first transverse cross section and at least one fiber area having a third transverse cross section less than said first transverse cross section; and
cooling said fiber to a temperature below the melting point temperature.
US Pat. No. 10,555,936

CHEMOTHERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING HUMAN GLIOMAS

THE METHODIST HOSPITAL, ...

1. A compound, comprising a targeting/seeker moiety that is specific for a mammalian monoamine oxidase B (MAO-B) enzyme, operably linked via a linker moiety to a therapeutic moiety that comprises a DNA acylating agent or a DNA damaging agent, wherein the therapeutic moiety is a neutral, blood-brain barrier-permeable pro-drug selected from the group consisting of a nitrogen mustard, a sulfur mustard, a platin tetranitrate, vinblastine, docetaxel, etoposide, SN38, camptothecin, carmustine, and any combination thereof, and further wherein the targeting/seeker moiety has a specificity for a MAO-B enzyme that is at least two-fold greater than its specificity for a MAO-A enzyme.
US Pat. No. 10,556,962

ANTI-OX40 ANTIBODIES AND THEIR USES

AbbVie Biotherapeutics In...


US Pat. No. 10,555,937

PHARMACEUTICAL COMPOSITIONS

XSPRAY MICROPARTICLES AB,...

19. A pharmaceutical composition, consisting of:(a) particles consisting of
(i) a protein kinase inhibitor having a degree of amorphicity of 100% in an amount of from about 10% by weight to about 70% by weight of the particles; and
(ii) copolyvidone; and
(b) an excipient;
wherein the protein kinase inhibitor is dasatinib, dasatinib hydrate, dasatinib solvate, dasatinib salt, or combinations thereof.
US Pat. No. 10,556,963

MEANS AND METHODS FOR COUNTERACTING MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISORDERS

AIMM THERAPEUTICS B.V., ...

1. An antibody, or a functional part thereof,wherein said functional part thereof is defined as a single chain variable fragment (scFv), a Fab fragment or a F(ab?)2 fragment;
wherein said antibody or functional part is able to bind a cell surface component of acute myeloid leukemia (AML) cells, comprising:
a heavy chain CDR1 sequence comprising SEQ ID NO: 209;
a heavy chain CDR2 sequence comprising SEQ ID NO: 213;
a heavy chain CDR3 sequence comprising SEQ ID NO: 217;
a light chain CDR1 sequence comprising SEQ ID NO: 221;
a light chain CDR2 sequence comprising SEQ ID NO: 225; and
a light chain CDR3 sequence comprising SEQ ID NO: 229; and
wherein said antibody is, synthetic or recombinant; and
wherein said antibody or functional part is coupled to a detectable label, a chemotherapeutic drug, a toxic moiety, a CD3-specific binding compound, another AML-specific binding compound, or a radioactive compound.
US Pat. No. 10,555,938

METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS

The Trustees of the Unive...

1. A method of treating a subject suffering from hyperlipidemia or hypercholesterolemia, the method comprising administering to the subject an effective amount of an MTP inhibitor, wherein said administration of the MTP inhibitor comprises three step-wise, increasing dose levels of the MTP inhibitor;wherein each of the dose levels is no more than 50% of the immediately following dose level;
wherein each of the dose levels is administered for about 1 to about 12 weeks;
wherein the MTP inhibitor is N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4?-(trifluoromethyl)[1,1?-biphenyl]-2-yl] carbonyl] amino]-1-piperidinyl]butyl]-9H-fluorene-9-carboxamide, methanesulfonate; and
wherein the administration of the MTP inhibitor reduces low-density lipoprotein cholesterol of the subject by at least 30% as compared to control blood levels.
US Pat. No. 10,556,964

BISPECIFIC ANTIBODY-MEDIATED CANCER THERAPY WITH CYTOKINE-INDUCED KILLER CELL

Wuhan YZY Biopharma Co., ...

1. A composition comprising a bispecific antibody bound to a cytotoxic immune cell,wherein the bispecific antibody comprises:
a) a monovalent unit comprising a light chain-heavy chain pair comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:3 and a light chain comprising the amino acid sequence of SEQ ID NO:5, and
b) a single chain variable fragment (scFv) comprising the amino acid sequence of SEQ ID NO:1, wherein the scFv binds to the cell.
US Pat. No. 10,555,939

FORMULATIONS OF 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE

Celgene Corporation, Sum...

1. An oral dosage form in the form of a capsule which comprises: 1) pomolidomide at an amount of 0.1 to 3 weight percent of the total weight of the composition; 2) a binder or filler at an amount of 70 to 99 weight percent of total weight of the composition, wherein the binder or filler is a mixture of mannitol and starch; and wherein the ratio of mannitol:starch in the dosage form is from about 1:1 to about 1:1.5.
US Pat. No. 10,555,940

PHOSPHODIESTERASE INHIBITOR TREATMENT

1. A method for treating hyposmia in a human comprising intranasally administering to the human a non-theophylline containing pharmaceutical composition comprising a therapeutically effective amount of a phosphodiesterase (PDE) inhibitor, wherein the PDE inhibitor is PDE-4 selective inhibitor that comprises roflumilast, and a pharmaceutically acceptable carrier, wherein the therapeutically effective amount comprises less than 1 mg of the PDE inhibitor.
US Pat. No. 10,556,966

ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES

Genentech, Inc., South S...

1. An isolated nucleic acid encoding an antibody that binds to HER2, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:15; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:16; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:17; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:12; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:13; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14.
US Pat. No. 10,556,967

ANTI-ADAM28 ANTIBODY FOR TREATING CANCER

GENEFRONTIER CORPORATION,...

1. An antibody specifically binding to human ADAM28 and having an activity to inhibit enzyme activity of human ADAM28, which antibody comprises a light chain variable region and a heavy chain variable region,wherein
the light chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 5, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 6, and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 7, and
the heavy chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 8, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 9, and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 10.
US Pat. No. 10,555,942

EMETINE COMPOUNDS FOR TREATMENT AND PREVENTION OF FLAVIVIRUS INFECTION

Florida State University ...

1. A method for treating or delaying the onset of Zika virus infection in a human or non-human animal subject, said method comprising administering an effective amount of cephaeline, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
US Pat. No. 10,556,968

BINDING MOLECULES SPECIFIC FOR CD73 AND USES THEREOF

MEDIMMUNE LIMITED, Cambr...

1. An isolated nucleic acid molecule encoding an antibody or antigen-binding fragment thereof that specifically binds to CD73, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain VH domain and a light chain VL domain, the heavy and light chain VH and VL domains comprising: (a) a VH CDR1 having the amino acid sequence of SEQ ID NO: 36: (b) a VH CDR2 having the amino acid sequence of SEQ ID NO: 39: (c) a VH CDR3 having the amino acid sequence of SEQ ID NO: 45: (d) a VL CDR1 having the amino acid sequence of SEQ ID NO: 46; (e) a VL CDR2 having the amino acid sequence of SEQ ID NO: 51: and (f) a VL CDR3 having the amino acid sequence of SEQ ID NO: 56.
US Pat. No. 10,556,969

CHIMERIC ANTIGEN RECEPTORS WITH AN OPTIMIZED HINGE REGION

CHEMOTHERAPETICSHES FORSH...

1. A nucleic acid sequence comprising nucleic acids encoding:a linker region that does not contain a cysteine residue and is selected from the following:
a) the amino acid sequence of SEQ ID NO. 2,
b) an amino acid sequence having at least 95% sequence identity to SEQ ID NO. 2 under the proviso that amino acid residue 48 is a serine, and
c) an amino acid sequence that differs in one, two or three amino acid residues from the amino acid sequence of SEQ ID NO. 2 under the proviso that amino acid residue 48 is a serine.
US Pat. No. 10,556,970

METHOD FOR PREPARING HIGH TRANSPARENT LOW ACYL GELLAN GUM

DSM IP ASSETS B.V., Te H...

1. A method for preparing purified deacylated gellan gum from gellan gum fermentation broth, wherein the method comprises the following steps:1) Deacylation of gellan gum present in fermentation broth, to obtain deacylated gellan gum solution, followed by two-stage filtration consisting of steps 2) and 3);
2) First filtration of the deacylated gellan gum solution obtained in step 1), wherein a first added filter aid and filter medium are diatomite and/or perlite with permeability of 1 ?m2-8 ?m2;
3) Second filtration of the gellan gum solution obtained in step 2), wherein a second added filter aid or filter medium comprises diatomite and/or perlite with permeability of 0.1 ?m2-1.0 ?m2; and
4) Alcohol precipitation of the gellan gum solution obtained in step 3), drying, and milling to obtain the gellan gum product.
US Pat. No. 10,556,972

PROCESS FOR THE POLYMERIZATION OF OLEFINS

Basell Poliolefine Italia...

1. A gas-phase process for the homopolymerization or copolymerization of olefins comprising the following steps:1) contacting, in a liquid hydrocarbon and in the absence of olefins, (a) a solid catalyst component comprising Ti, Mg, and Cl, and optionally an internal electron donor compound (ID), (b) an aluminum alkyl compound and optionally (c) an external donor compound; and
2) feeding a product of the contacting step 1) to a gas-phase polymerization reactor under polymerization conditions, wherein the contacting step 1) is carried out in the presence of H2 in an amount ranging from 0.1 to 8 g per kg of solid catalyst component (a).
US Pat. No. 10,555,947

OPHTHALMIC COMPOSITIONS AND METHODS OF USE

OCUGEN, INC., Malvern, P...

1. An ophthalmic composition comprising: an alpha 2 adrenergic agonist and cyclosporin.
US Pat. No. 10,556,974

CURABLE AND HYGROSCOPIC RESIN COMPOSITION FOR SEALING ELECTRONIC DEVICES, SEALING RESIN, AND ELECTRONIC DEVICE

FURUKAWA ELECTRIC CO., LT...

1. A curable and hygroscopic resin composition for sealing electronic devices, comprisingfrom 5 to 30 mass % of at least a (meth)acrylate oligomer (a) having a number-average molecular weight of 1,500 to 5,000,
from 40 to 90 mass % of a low molecular weight (meth)acrylate (b) having an average molecular weight of 170 to 500,
from 5 to 30 mass % of a moisture-reactive organometallic compound (c), and
a polymerization initiator (d),
wherein the (meth)acrylate oligomer (a) and the low molecular weight (meth)acrylate (b) are multifunctional (meth)acrylates in which the number of (meth)acryloyl groups is from 1.5 to 3 in one molecule of each of the (meth)acrylate oligomer (a) and the low molecular weight (meth)acrylate (b); and
wherein the (meth)acrylate oligomer (a) is a resin whose main chain is a polybutadiene or a hydrogenated polybutadiene.
US Pat. No. 10,557,486

USE OF TREATING ELEMENTS TO FACILITATE FLOW IN VESSELS

CRYSTAPHASE PRODUCTS, INC...

1. A method of improving flow distribution of one or more streams in a process vessel comprising:passing the one or more streams through an upstream processing zone and a downstream processing zone within the process vessel, the upstream processing zone and downstream processing zone each containing one or more beds of processing materials; and
passing the one or more streams through a redistribution treating zone located between the upstream processing zone and downstream processing zone,
wherein the redistribution treating zone has a depth of four feet or less and contains treating elements,
and wherein the redistribution treating zone mitigates stream channeling of the streams exiting the upstream processing zone and affects lateral redistribution of the flow of the one or more streams within the downstream processing zone,
and wherein the treating elements have more than one opening passing therethrough,
and wherein the treating elements have asperities formed on the surfaces thereof, the asperities comprising one or more of flutes, fins and struts,
and wherein the treating elements have one or more open cells which form a plurality of interconnected fluid flow pathways within and through each treating element,
and wherein the treating elements are up to 100 times the size of the individual processing materials within the process vessel.
US Pat. No. 10,557,231

METHOD FOR COLORING CELLULOSE

1. A process for coloring cellulose in supercritical CO2 medium with a hydrophobic dye, comprising at least the steps:(i) providing cellulose fibers,
(ii) placing said cellulose fibers in contact with:
a) an effective amount of at least one uncharged primary monoorganourea selected from the group consisting of 4-methoxyphenylurea and octadecylurea, under conditions suitable for establishing a covalent bond of carbamate type between the cellulose and each molecule of said organourea; and
b) at least one hydrophobic dye, in supercritical CO2 medium, under conditions suitable for immobilizing said dye on said fibers.
US Pat. No. 10,555,951

TARGETED TREATMENT OF LEIOMYOSARCOMA

ELI LILLY AND COMPANY, I...

1. A method of treating a patient suffering from leiomyosarcoma, the method comprising:administering to a patient determined to have advanced or metastatic leiomyosarcoma an effective amount of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof.
US Pat. No. 10,556,977

DILUENT FOR THE PRODUCTION OF BUTYL RUBBER

ARLANXEO CANADA INC., Sa...

1. A process for the preparation of elastomers, the process comprising:polymerizing at least two monomers comprising at least one isoolefin and at least one multiolefin within a reaction medium comprising an organic diluent, and in the presence of an initiator system to form an organic medium slurry comprising elastomer, the organic diluent, and optionally residual monomers,
whereby the organic diluent comprises
48 to 52 vol.-% of methyl chloride, and
48 to 52 vol.-% 1,1,1,2-tetrafluoroethane, and
the methyl chloride and tetrafluoroethane add up to 90 to 100 vol.-% of the total volume of organic diluent.
US Pat. No. 10,555,952

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS

Melt Pharmaceuticals, Inc...

1. A method for treating or mitigating sedative-induced nystagmus in a patient in need of conscious sedation, procedural sedation, analgesia, pre-sedation or a non-general anesthesia prior to undergoing a medical procedure comprising administering to the patient an effective amount of a pharmaceutical composition, the pharmaceutical composition comprising:(a) a therapeutically effective quantity of a first pharmaceutically active compound selected from the group consisting of midazolam, diazepam, lorazepam, flunitrazepam, alprazolam, chlordiazepoxide, clonazepam and clorazepate, and pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof;
(b) a therapeutically effective quantity of a second pharmaceutically active compound selected from the group consisting of ketamine, dextrorphan, etomidate, methadone, memantine, amantadine, dextromethorphan, and pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof;
(c) optionally, a pharmaceutically suitable binder therefor; and
(d) optionally, a pharmaceutically acceptable excipient,
thereby preventing or mitigating the occurrence of sedative-induced nystagmus resulting from administering the second pharmaceutically active compound alone to the patient for conscious sedation, procedural sedation, analgesia, pre-sedation or a non-general anesthesia.
US Pat. No. 10,556,978

PROCESS AND CHEMISTRY FOR REDUCING DOLOMITE CONCENTRATIONS IN PHOSPHATE PROCESSING

Arr-Maz Products, L.P., ...

1. A method of reducing dolomite concentrations in phosphate processing, the method comprising:adding magnesium flocculant to phosphate rock during processing at a chemical plant; and wherein the magnesium flocculant is a polymer comprising:
a base monomer comprising acrylic acid, acrylamide, or a combination of acrylic acid and acrylamide: and
a functional monomer comprising hydroxyl ethyl methacrylate, 2-acrylamido-2-propane sulfonic acid, 3-allyl-1, 2-propanediol, and/or a derivative thereof.
US Pat. No. 10,557,234

PAPERMAKING ADDITIVE COMPOSITIONS AND METHODS AND USES THEREOF

Neozyme International, In...

1. A papermaking additive composition comprising a treated, fermented yeast supernatant including bio-nutrients, minerals and amino acids, and about 1% to about 15% by weight of one or more nonionic surfactants, wherein the composition lacks any active enzymes due to the treatment, and wherein the composition has a pH of about 2.5 to about 5.0.
US Pat. No. 10,555,953

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INCREASED INTRAOCULAR PRESSURE

NOVALIQ GMBH, Heidelberg...

1. A pharmaceutical composition comprising:(a) a therapeutically effective amount of a poorly water-soluble prostaglandin analogue selected from the group consisting of latanoprost, bimatoprost, tafluprost, travoprost and unoprostone, and
(b) a liquid vehicle comprising a semifluorinated alkane selected from F4H5, F4H6, F6H6 and F6H8;wherein the composition is substantially free of water and free of a preservative, andwherein the composition is formulated as a solution, emulsion or suspension.
US Pat. No. 10,556,980

POLY ALKYL (METH)ACRYLATES GRAFTED NANOPARTICLES AND THEIR METHODS OF MANUFACTURE AND USE

University of South Carol...

1. A method of synthesizing a composite, the method comprising:covalently bonding a plurality of an anchoring compound to a nanoparticle;
covalently bonding a plurality of reversible addition-fragmentation chain-transfer (RAFT) agents to the anchoring compounds bonded to the nanoparticle, each of the RAFT agents being bonded to each one of the anchoring compounds;
polymerizing a stearyl methacrylate monomers to each one of the RAFT agents bonded to the anchoring compounds in a solvent solution comprising a mixture of solvents to form a graft-modified nanoparticle that includes a plurality of poly(stearyl methacrylate) (PSMA) polymer chains bonded to the nanoparticle, each of the PSMA polymer chains being bonded to each one of the RAFT agents via direct bonding between a terminal stearyl methacrylate of the PSMA polymer chain and the RAFT agent, the PSMA polymer chains consisting of PSMA polymer chains having a number average molecular weight of from 84,000 to 140,000 that are grafted to the nanoparticle at a chain density of from 0.11 chains per nm2 to 0.7 chains per nm2;
following the polymerization step, combining a plurality of the thus produced graft-modified nanoparticles with a polypropylene or a polyethylene to form a mixture; and
solution casting or melt-forming the mixture to form the composite of a polypropylene or polyethylene matrix with the plurality of the graft-modified nanoparticles dispersed therein without gross agglomeration of the nanoparticles within the polypropylene or polyethylene matrix.
US Pat. No. 10,555,956

CHEMOPREVENTION OF COLORECTAL CANCER

SOFAR SPA, Trezzano Rosa...

1. A combination, comprising:(i) a 5-aminosalicylic acid component, wherein the 5-aminosalicylic acid component comprises 5-aminosalicylic acid or a pharmacologically acceptable salt of 5-aminosalicylic acid; and
(ii) a group D vitamin component, wherein the group D vitamin component is selected from the group consisting of vitamin D3, vitamin D2, 25-hydroxy-vitamin D3 and 1-alpha,25 dihydroxy-vitamin D3;
wherein the combination includes between 0.5 grams and 5 grams of the 5-aminosalicylic acid component and between 500 international units and 10,000 international units of the group D vitamin component; and
wherein the combination does not include calcium.
US Pat. No. 10,556,982

THERMOPLASTIC POLYURETHANE RESIN COMPOSITION HAVING ENHANCED TEXTURE AND DURABILITY AND PRODUCTION METHOD THEREOF

Hyundai Motor Company, S...

1. A thermoplastic polyurethane resin composition comprising:isocyanate compound;
a polyester polyol; and
a chain extender,
wherein the polyester polyol is prepared from a mixture of reactants including polytetramethylene ether glycol and polydimethylsiloxane diol,
wherein the polyester polyol is prepared from a mixture of reactants including a multifunctional carboxylic acid compound, a multifunctional alcohol compound, polytetramethylene ether glycol and polydimethylsiloxane diol, and
wherein the multifunctional alcohol compound is one or more selected from a group consisting of one or more diols selected from a group consisting of ethylene glycol, butane diol, and hexane diol; and trimethylol propane.
US Pat. No. 10,556,984

CHEMICALLY DECOMPOSABLE EPOXIDE RESIN SYSTEM

11. A method of constructing reinforced plastic components for use in aeroplanes, in rail vehicle construction, in wind energy plants, and in the automotive industry, comprising the steps of:(a) forming a cured component of a curable epoxide resin system; and
(b) using such cured component and when finished using such cured component, recycling the epoxide resin system forming the cured component by chemically decomposing the cured component by aminolysis with reactive NH2— or other amino groups and/or alcoholysis with mono-, di-, or poly functional alcohols,
wherein the curable epoxide resin system forming the cured component comprises one or more epoxide resins and one or more curing agents; wherein the one or more curing agents comprise at least one cyanate with the formula R—O—C?N, wherein R is an organic residue which is aromatic, partially halogenated-aliphatic or perhalogenated-aliphatic; wherein the at least one cyanate is present in amount such that cyanate groups constitute at least 30% of reactive functional groups present in the curable epoxide resin system; and wherein the cured product comprises an epoxide resin polymer and cyanurates.
US Pat. No. 10,555,959

GLYCOLIPIDS AS TREATMENT FOR DISEASE

La Jolla Pharmaceutical C...

1. A method of treating a subject having a GM3 deficiency, comprising administering to the subject a therapeutic amount of a compound selected from GM1 and GD1a.
US Pat. No. 10,556,217

CURED BIODEGRADABLE MICROPARTICLES AND SCAFFOLDS AND METHODS OF MAKING AND USING THE SAME

THE SECANT GROUP, LLC, T...

1. A method of forming a pressure-sensitive adhesive comprising:combining an uncured polymeric ester resin and at least one controlled release agent to form an ester phase of the uncured polymeric ester resin loaded with the at least one controlled release agent; and
combining the ester phase comprising the uncured polymeric ester resin and the at least one controlled release agent with an elastomer phase comprising an elastomeric polymer resin, at a ratio of ester phase:elastomer phase selected to provide the ester phase as a dispersed discontinuous microspherical phase in a continuous matrix of the elastomer phase, to form a pressure-sensitive adhesive composition.
US Pat. No. 10,556,729

GAS BARRIER PACKAGING MATERIAL PRECURSOR AND GAS BARRIER PACKAGING MATERIAL

TOPPAN PRINTING CO., LTD....

1. A gas barrier packaging material precursor, comprising:a support;
an adhesion layer provided on one surface of the support;
a barrier layer and a protective layer formed adjacent to each other on the adhesion layer,
wherein said precursor has a laminated structure in which the adhesion layer, the barrier layer and the protective layer are formed in this order on the surface, alternatively, the adhesion layer, the protective layer, and the barrier layer are formed in this order on the surface;
wherein the adhesion layer contains a composite of a silicon compound having an isocyanate group or a hydrolysate of the compound, an acrylic polyol, or an isocyanate compound;
the barrier layer comprises a polycarboxylic acid polymer and at least one silicon compound (III) selected from the group consisting of a silane coupling agent represented by a general formula Si(OR)3Z, a hydrolysate thereof, and a condensate of these materials, wherein R denotes an alkyl group having 1 to 6 carbon atoms, Z denotes an organic group containing a glycidyloxy group or an amino group, and each R may be the same or different from each other;
wherein the protective layer being formed of a coating liquid containing a polyvalent metal compound, a polyester resin, and a dispersant; and the protective layer containing the polyvalent metal compound by about 40 to about 90 mass % relative to 100 mass % of the protective layer;
and wherein when the barrier layer is separated from the gas barrier packaging material precursor to measure an infrared absorption spectrum of the barrier layer by a transmission method, a ratio (?/?) of a maximum peak height (?) of absorbance in a range of about 1490 to about 1659 cm?1 to a maximum peak height (?) of absorbance in a range of about 1660 to about 1750 cm?1 is less than about 1,
wherein the acrylic polyol of the adhesion layer has a hydroxyl value in a range of 5 to 200 KOH mg/g.
US Pat. No. 10,556,218

COMPOSITIONS AND METHODS FOR ENTRAPPING PROTEIN ON A SURFACE

PURE TRANSPLANT SOLUTIONS...

1. A method of printing Human Leukocyte Antigen (HLA) proteins onto a substrate, comprising:providing a solid substrate;
applying a formulation comprising HLA proteins onto the solid substrate; and
irradiating the formulation to trap the HLA proteins to the substrate, thereby producing a matrix that indirectly attaches the HLA proteins to the solid substrate and retains the native three dimensional structure of the HLA proteins while the HLA proteins are indirectly attached to the solid substrate.
US Pat. No. 10,559,805

BATTERY FOR AN ELECTRIC VEHICLE

GM Global Technology Oper...

1. A battery module for a battery pack, the battery module comprising:a plurality of first battery cells and a plurality of second battery cells that define a first lateral side, a second lateral side, an additional side and a center region between the plurality of first battery cells and the plurality of second battery cells;
a first outer bus bar disposed proximate to the first lateral side, and operatively configured to couple the plurality of first battery cells to a first outer connecting bus bar;
a second outer bus bar disposed proximate to the second lateral side, and operatively configured to couple the plurality of second battery cells to a second outer connecting bus bar;
a first inner bus bar disposed proximate to the center region, the first inner bus bar having a first proximate end and a first distal end, and the first proximate end is affixed to a corresponding first cell tab of the plurality of first battery cells; and
a second inner bus bar disposed proximate to the center region, the second inner bus bar having a second proximate end and a second distal end, and the second proximate end is affixed to a corresponding second cell tab of the plurality of second battery cells.
US Pat. No. 10,555,961

MATERIALS AND METHODS FOR TREATING BACTERIAL INFECTIONS USING C-1 GENTAMICIN

INDIANA UNIVERSITY RESEAR...

1. A method of treating a condition in a subject comprising administering a composition comprising C-1 gentamicin or a pharmaceutically acceptable acid addition salt thereof, wherein the composition is substantially free of C-1a gentamicin, C-2 gentamicin and C-2a gentamicin, and the condition is selected from the group consisting of a bacterial infection, a monogenic genetic disease and cancer.
US Pat. No. 10,555,962

USE OF ICARITIN IN PREPARING MEDICAMENT FOR PREVENTING OR TREATING HEMATOCYTOPENIA

Lunan Pharmaceutical Grou...

1. A method for treating hematocytopenia comprising administering a composition comprising an effective amount of icaritin, as the sole active ingredient of the composition, to a human suffering from hematocytopenia, wherein the hematocytopenia is bone marrow suppression induced by radiation or a chemotherapeutic drug for treating cancer, or primary myelodysplasia.
US Pat. No. 10,555,963

KLOTHO PROTEIN AND RELATED COMPOUNDS FOR THE TREATMENT AND DIAGNOSIS OF CANCER

TEL HASHOMER MEDICAL RESE...

1. A method of treatment by inhibiting tumor growth or reducing tumor size in a subject having cancer, comprising administering to a subject in need thereof a pharmaceutically effective amount of a composition comprising an isolated polypeptide consisting of an amino acid sequence having at least 80% homology to the amino acid sequence represented by SEQ ID NO: 2, or a DNA encoding therefor, wherein the pharmaceutically effective amount is effective in inhibiting tumor growth or reducing tumor size in the patient.
US Pat. No. 10,556,989

END-MODIFIED POLYAMIDE RESIN AND METHOD FOR PRODUCING SAME

TORAY INDUSTRIES, INC., ...

1. An end modified polyamide resin containing 1 to 20% by mass of an end structure represented by general formula (I) below and 0.1 to 5% by mass of an end structure represented by general formula (II) below:—X—(R1—O)m—R2  (I)
wherein m represents 2 to 100; R1 represents a divalent hydrocarbon group having 2 to 10 carbon atoms, and R2 represents a monovalent hydrocarbon group having 1 to 30 carbon atoms; and —X— represents —NH—, —N(CH3)— or —(C?O)—; and m R1s in the general formula (I) may be the same or different, and
—Y—R3  (II)
wherein R3 represents a monovalent hydrocarbon group having 1 to 30 carbon atoms; and —Y— in the general formula (II) represents —(C?O)— when X in the general formula (I) is —NH— or —N(CH3)—, Y in the general formula (II) represents —NH— or —N(CH3)— when X in the general formula (I) is —(C?O)—.
US Pat. No. 10,555,966

BINDING OF GALECTIN-3 BY LOW MOLECULAR WEIGHT PECTIN

ECONUGENICS, INC., Santa...

1. A method of treating a mammal which benefits from a reduction in available circulating galectin-3, comprising the steps of:a) Identifying a mammal in need of treatment for chronic heart failure, and
b) Administering to said mammal an amount of modified pectin of molecular weight of 3,000-13,000 Daltons, in an amount of 10-750 mg/kg/day, for a period of time sufficient such that said mammal exhibits a reduction in active galectin-3 levels in said mammal and thereby treat chronic heart failure in said mammal.
US Pat. No. 10,555,967

COMPOSITIONS PREPARED FROM POULTRY AND METHODS OF THEIR USE

INTERNATIONAL DEHYDRATED ...

1. A composition prepared from poultry parts, said composition comprising an enhanced quantity of chondroitin sulfate and having certain ratio between amino acids proline and histidine derived from said poultry parts, wherein the amount of chondroitin sulfate derived from said poultry parts is at least 6% by weight of total dry solids of the composition, and wherein said certain ratio between proline and histidine derived from said poultry parts is at least 4:1 by weight, said composition being in solid or liquid form, wherein at least 50% of proteins in said composition have a molecular weight of between 15 kD and 70 kD.
US Pat. No. 10,556,225

METHODS OF REGENERATING AROMATIZATION CATALYSTS WITH A DECOKING STEP BETWEEN CHLORINE AND FLUORINE ADDITION

Chevron Phillips Chemical...

1. A method for regenerating a chlorinated spent catalyst comprising a transition metal and a catalyst support, the method comprising:(i) contacting the chlorinated spent catalyst with a decoking gas stream comprising oxygen to produce a de-coked chlorinated catalyst,
wherein the chlorinated spent catalyst comprises from about 0.5 wt. % to about 3 wt. % of chlorine; and
(ii) contacting the de-coked chlorinated catalyst with a fluorine-containing solution comprising a fluorine-containing compound in the liquid phase to produce a fluorinated catalyst; wherein:
the transition metal comprises a Group 8-11 transition metal; and
the catalyst support comprises a large pore zeolite having an average pore diameter in a range of from about 7 ? to about 12 ?.
US Pat. No. 10,556,993

ADDITION-CURABLE ORGANOPOLYSILOXANE RESIN COMPOSITION, CURED PRODUCT THEREOF, AND SEMICONDUCTOR DEVICE HAVING THE CURED PRODUCT

SHIN-ETSU CHEMICAL CO., L...

5. A cured product of an addition-curable organopolysiloxane resin composition comprising:(A) an organopolysiloxane having in one molecule at least two silicon-atom-bonded alkenyl groups each having 2 to 10 carbon atoms, said organopolysiloxane being present in an amount of 60 to 90% by mass per a total amount of components (A) to (D);
(B) an organohydrogenpolysiloxane having in one molecule at least two silicon-atom-bonded hydrogen atoms, said organohydrogenpolysiloxane being present in an amount of 5 to 40% by mass per the total amount of components (A) to (D);
(C) a platinum group metal-based catalyst, said platinum group metal-based catalyst being present in an amount of 0.00001 to 0.01% by mass in terms of platinum group metal per the total amount of components (A) to (D); and
(D) a barium compound that is present in an amount of 0.001 to 10.0% by mass per the total amount of components (A) to (D), wherein component (D) comprises at least one compound selected from dimethoxy barium, diethoxy barium, diisopropoxy barium, di-n-propoxy barium, di-n-butoxy barium, diisobutoxy barium, di-sec-butoxy barium, di-t-butoxy barium, barium octanoate, and barium 2-ethylhexanoate.
US Pat. No. 10,559,813

NEGATIVE ELECTRODE FOR NONAQUEOUS ELECTROLYTE SECONDARY BATTERY AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY

KABUSHIKI KAISHA TOYOTA J...

1. A negative electrode for nonaqueous electrolyte secondary battery, the negative electrode comprising:a current collector;
a negative electrode active material layer arranged on a surface of the current collector; and
a protective layer arranged on a top surface of the negative electrode active material layer;
the negative electrode active material layer including an active material layer binder, and a first negative electrode active material having an aspect ratio defined as “a”/“b” to fall in a range of from two or more to eight or less when a length of a major axis thereof is defined “a” and a length of a minor axis thereof is defined “b”;
the protective layer including a ceramic powder.
US Pat. No. 10,555,713

METHODS FOR TREATING IDIOPATHIC PULMONARY FIBROSIS

FIBROGEN, INC, San Franc...

1. A method for increasing forced vital capacity percent predicted (FVC % predicted) in a subject with idiopathic pulmonary fibrosis (IPF), the method comprising administering at least 30 mg/kg of an anti-connective tissue growth factor (CTGF) antibody that has the same amino acid sequence as the antibody produced by the cell line identified by ATCC Accession No. PTA-6006, thereby increasing the subject's FVC % predicted.
US Pat. No. 10,555,969

ZEOLITE MOLECULAR SIEVES FOR THE REMOVAL OF TOXINS

FRAMEWORK THERAPEUTICS, L...

1. A method of treating or palliating elevated human blood ammonia levels, comprising administering to a human suffering from hepatic encephalopathy or cirrhosis of the liver, a pharmaceutical formulation comprising a synthetic sodium aluminosilicate zeolite and a pharmaceutically acceptable adjuvant, wherein:(a) the synthetic sodium aluminosilicate is particulate and at least 90% of the particles are of particle size from about 90 ?m to about 150 ?m;
(b) the formulation is from about 50% (w/w) to about 95% (w/w) water; and
(c) the formulation is administered in a doses of from 2 g to 15 g sodium aluminosilicate up to 4 times per day.
US Pat. No. 10,556,227

CRYSTALLINE AMMONIA TRANSITION METAL MOLYBDOTUNGSTATE


US Pat. No. 10,556,995

PROCESS FOR MAKING A COMPOSITION COMPRISING BENEFIT AGENT DELIVERY PARTICLES

1. A process of making a feedstock composition comprising benefit agent delivery particles, said process comprising the steps of:combining a graft co-polymer and a benefit agent to form a premix composition,
wherein said graft co-polymer is a co-polymer of polyalkylene glycol and vinyl acetate that comprises a polyalkylene glycol backbone comprising vinyl acetate moieties that are covalently attached to said polyalkylene glycol backbone,
wherein said benefit agent comprises perfume oil,
and
combining said premix composition and water to form said feedstock composition,
wherein said feedstock composition comprises less than about 98%, by weight of the feedstock composition, of water; and
wherein said benefit agent delivery particles comprise said graft co-polymer and said benefit agent.
US Pat. No. 10,555,970

COLON LAVAGE SYSTEM

DARK CANYON LABORATORIES,...

1. A kit for patient preparation prior to a colon-related medical procedure, comprising:a) a plurality of individually packaged unit doses from 25 g to 175 g of an osmotic agent formulated for administration to a patient after dissolving in water, wherein said plurality of individually packaged unit doses of an osmotic agent do not contain electrolytes; and separately,
b) a plurality of individually packaged unit doses of a composition comprising electrolytes, wherein said electrolytes are in a pill, tablet, capsule, gel-cap, or micro-encapsulated granules.
US Pat. No. 10,556,228

ACIDIC AROMATIZATION CATALYST WITH IMPROVED ACTIVITY AND STABILITY

Chevron Phillips Chemical...

1. A supported catalyst comprising:a bound zeolite base, wherein the bound zeolite base comprises a binder and a large pore zeolite having an average pore diameter in a range of from about 7 ? to about 12 ?;
from about 0.3 wt. % to about 3 wt. % of a transition metal, wherein the transition metal comprises a Group 8-11 transition metal;
from about 1.8 wt. % to about 4 wt. % of chlorine; and
from about 0.4 wt. % to about 1.5 wt. % of fluorine, based on the total weight of the supported catalyst;
wherein the supported catalyst is characterized by a peak reduction temperature on a Temperature Programmed Reduction curve in a range from about 580° F. to about 800° F.
US Pat. No. 10,556,740

SYSTEM OF PERSONAL CARE PRODUCTS FOR HUMAN DEVELOPMENTAL STAGES

1. A system of personal care products comprising:a. a first personal care product for stage 1 of a human life, wherein stage 1 of a human life is generally from birth to about six months of life, the first personal care product including a first package that includes a simple color and one simple shape, the first personal care product having a high mildness score, being free of dye, and having a first formulation attribute designed for the human at stage 1 of life, wherein at least one first formulation attribute is fragrance, and wherein the fragrance is a fragrance associated with simple foods;
b. a second personal care product for stage 2 of a human life, wherein stage 2 of a human life is generally from about six months of life to about 18 months of life, the second personal care product including a second package that includes at least one more color than the first personal care product, and the second package having at least two different simple shapes, the second personal care product having a second formulation attribute designed for the human at stage 2 of life wherein the second formulation attribute is different than the first formulation attribute, wherein at least one second formulation attribute is fragrance, and wherein the fragrance is selected from the group consisting of a fragrance that resembles a single fruit or other fragrant food or a fragrance that resembles a simple blend of food;
c. a third personal care product for stage 3 of a human life, wherein stage 3 of human life is generally from about 18 months of life to about 3 years of life, the third personal care product including a third package that includes more colors than the second personal care product, the third package including complex shapes, the third personal care product having a third formulation attribute designed for the human at stage 3 of life wherein the third formulation attribute is different than the second formulation attribute, wherein at least one third formulation attribute is fragrance, and wherein the fragrance is a fragrance associated with the group consisting of floral, non-food related and complex blends of foods,
wherein the personal care products are selected from group consisting of wash, lotion, shampoo, bubble bath, cream, oil, butter, solid oil, powder, bar, wipe, cologne, conditioner, cleansing water, liquid powder, oil to powder, ointment, and gel;
wherein each stage defines a period of time in which a human has reached or is in the process of reaching at least two developmental milestones selected from cognitive developmental milestone, emotional developmental milestone, social developmental milestone and/or physical developmental milestone.
US Pat. No. 10,555,971

COMBINED ORGAN AND HEMATOPOIETIC CELLS FOR TRANSPLANTATION TOLERANCE OF HLA MISMATCHED GRAFTS

The Board of Trustees of ...

1. A kit comprising components for an engineered hematopoietic cell product for establishing mixed chimerism in a solid organ transplant recipient, wherein the components of the engineered hematopoietic cell product comprise:an effective amount of CD34+ cells/kilogram recipient weight, wherein the CD34+ cells are derived from a donor that is of an HLA type that is mismatched to the solid organ transplant recipient's HLA type; and
more than 1×107 CD3+ T cells/kilogram recipient weight, wherein the CD3+ cells are derived from the donor that is of an HLA type that is mismatched to the solid organ transplant recipient's HLA type.
US Pat. No. 10,556,229

COMPOSITE CATALYST, METHOD FOR PRODUCING COMPOSITE CATALYST, METHOD FOR PRODUCING LOWER OLEFIN AND METHOD FOR REGENERATING COMPOSITE CATALYST

CHIYODA CORPORATION, Yok...

1. A composite catalyst for producing a lower olefin from a hydrocarbon feedstock, comprising:a zeolite being a crystalline aluminosilicate containing gallium and iron or iron in the framework of the zeolite and further having a framework with 8- to 12-membered ring; and
silicon dioxide,
wherein
when the zeolite is a crystalline aluminosilicate containing iron and gallium, and
an acid density as a composition ratio of the number of moles of silicon to a sum of the number of moles of iron, gallium, and aluminum is 75.0 to 200.0, a composition ratio of the number of moles of gallium to a sum of the number of moles of iron, gallium, and aluminum is 0.1 to 0.4, and a composition ratio of the number of moles of iron to a sum of the number of moles of iron, gallium, and aluminum is 0.2 to 0.6,
and
when the zeolite is a crystalline aluminosilicate containing iron, and
an acid density as a composition ratio of the number of moles of silicon to a sum of the number of moles of iron and aluminum is 75.0 to 200.0, and a composition ratio of the number of moles of iron to a sum of the number of moles of iron and aluminum is 0.4 to 0.7.
US Pat. No. 10,556,997

CROSS-LINKED RUBBER PRODUCT

ZEON CORPORATION, Tokyo ...

1. A cross-linked rubber product obtained by cross-linking an acrylic elastomer composition containing an acrylic elastomer obtained by copolymerization of an acrylate and a cross-linking site monomer having a carboxyl group,wherein a molar fraction of an oxygen atom (a) in the acrylic elastomer is 11.3 mol % or less,
a molar fraction of a nitrogen atom (b) in the acrylic elastomer is 0.5 mol % or less,
a content of n-butyl acrylate unit in a monomer unit constituting the acrylic elastomer is from 78 to 99.9% by weight, and
a volume change is from -3 to 6% when the cross-linked rubber product punched into a size of a length of 30 mm, a width of 20 mm, and a thickness of 2.0±0.2 mm is dipped in distilled water at 80° C. for 200 hours.
US Pat. No. 10,559,816

SURFACE-TREATED POSITIVE ELECTRODE ACTIVE MATERIAL FOR LITHIUM SECONDARY BATTERY, METHOD FOR PREPARING THE SAME, AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME

LG Chem, Ltd., (KR)

1. A positive electrode active material for a lithium secondary battery comprising:lithium transition metal composite oxide particles; and
a coating layer including LiwNbxOy (1?w?8, 1?x?13, 1?y?20) formed on surfaces of the lithium transition metal composite oxide particles,wherein the lithium transition metal composite oxide particles are represented by the following Chemical Formula 1:Li1+z[NiaCobMnc]O2 (0?z?0.6, 0.6?a?1, 0?b, c?1, z+a+b+c=1), and  [Chemical Formula 1]
wherein the coating layer further includes Li2O—Nb2O5,
wherein the coating layer is included in 0.05% by weight to 3% by weight with respect to a total weight of the positive electrode active material.
US Pat. No. 10,555,972

THERAPEUTIC EFFECTS OF NURR1 AND FOXA2 IN INFLAMMATORY NEUROLOGIC DISORDERS BY M1-TO-M2 POLARIZATION OF GLIAL CELLS

INNOPEUTICS CORPORATION, ...

1. A method of protecting brain neurons from cell damage comprising:administering to a mammal a recombinant viral vector comprising a nucleic acid expressing Nuclear receptor-related factor 1 (Nurr1) and forkhead box protein A2 (Foxa2) to transduce glial cells that are adjacent to neurons to form transduced glial cells; and
expressing Nurr1 and Foxa2 proteins from the recombinant viral vector, wherein expression of both Nurr1 and Foxa2 proteins in the transduced glial cells reduces secretion of one or more inflammatory factors and increases secretion of one or more neurotrophic factors that protect the neurons from cell damage relative to transduced glial cells expressing Nurr1 or Foxa2 alone.
US Pat. No. 10,559,817

SULFUR PARTICLES COATED WITH INORGANIC-ORGANIC HYBRID MEMBRANES AS CATHODE ACTIVE MATERIAL AND BATTERIES CONTAINING THE PARTICLES

1. A core-shell composite sulfur particle, comprising:a core of elemental sulfur comprising homogeneously dispersed particles of a conductive carbon and a polyelectrolyte polymer; and
a shell of a hybrid membrane comprising in sequence from a surface of the core, a layer of branched polyethyleneimine (bPEI), a layer of a negatively charged smectite clay nanosheet and a layer of bPEI on the layer of negatively charged smectite clay nanosheet encapsulating the core;
wherein the dispersed particles of conductive carbon are associated with the polyelectrolyte polymer of the elemental sulfur core, and
the polyelectrolyte polymer of the core is selected from the group consisting of a branched polyethyleneimine, poly(3,4-ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS) and polyvinyl pyrrolidone (PVP).
US Pat. No. 10,555,973

THERAPEUTIC COMPOSITIONS

University of Utah Resear...

1. A therapeutic composition, comprising:an amount of processed amniotic fluid having a therapeutically effective amount of protein and hyaluronic acid (HA), said composition being substantially free of lanugo, vernix, and cells harvested with amniotic fluid, wherein the protein is present in an amount from about 0.15 mg/ml to about 10 mg/ml and wherein the composition is lyophilized and has an optical density of less than 0.20 when exposed to electromagnetic radiation at a wavelength of 590 nm in a liquid form.
US Pat. No. 10,556,999

PURIFICATION AND DECOLORIZATION OF POLYMERS

Tolmar, Inc., Fort Colli...

1. A method for preparing a polymer composition comprising a polymer and a solvent, comprising:(a) adding a metal scavenger to the polymer composition to form a complex with a metal contaminant in the polymer composition;
(b) separating the metal scavenger and metal contaminant complex from the polymer;
(c) adding a photocatalyst to the polymer composition;
(d) exposing the polymer composition to ultraviolet (UV) light to remove color from the polymer composition; and
(e) separating the photocatalyst from the polymer composition.
US Pat. No. 10,555,975

PREVOTELLA HISTICOLA PREPARATIONS AND THE TREATMENT OF AUTOIMMUNE CONDITIONS

Mayo Foundation for Medic...

1. A powder composition comprising:(a) an anti-inflammatory effective amount of live Prevotella histicola or dead Prevotella histicola, and
(b) a botanical.
US Pat. No. 10,555,976

METHOD OF REDUCING THE LIKELIHOOD OF SKIN CANCER IN AN INDIVIDUAL HUMAN BEING

1. A method of reducing the likelihood of skin cancer in an individual human being, said method comprising: administering a therapeutically effective amount of a bacterial formulation comprising Nitrosomonas eutropha adapted to produce p53, said bacterial formulation comprising a lotion, ointment or gel adapted to be rubbed onto a region of an individual's skin wherein at least some bacteria in the bacterial formulation have been modified by using a using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1(Cpf1) system to remove a virulence factor of the at least some bacteria.
US Pat. No. 10,559,821

CATHODE ACTIVE MATERIAL AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME

LG Chem, Ltd., (KR)

1. A lithium secondary battery comprising:a cathode comprising a cathode active material consisting of:
a compound of formula 1:
(1?s?t)[Li(LiaMn(1?a?x?y)NixCoy)1?a)O2]*s[Li2CO3]*t[LiOH]  (1)
wherein 0 a, x and y represent a molar ratio, and s and t represent a weight ratio,
an anode,
a separator, and
a non-aqueous electrolyte,
wherein a cycle capability of the lithium secondary battery at 30th cycle is 94% or more.
US Pat. No. 10,555,977

PROBIOTIC BACTERIA FOR THE TOPICAL TREATMENT OF SKIN DISORDERS

DuPont Nutrition Bioscien...

1. A method for treating a disorder associated with Tight Junction function in a patient in need thereof, wherein:the method comprises topically administering a formulation comprising an effective amount of a probiotic bacteria, a soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria;
the probiotic bacteria is Propionibacterium jensenii P63; and
the disorder is selected from the group consisting of psoriasis, acne, atopic dermatitis, dry skin, allergy, rashes, UV-irritated skin, detergent irritated skin, thinning skin and asthma.
US Pat. No. 10,555,978

COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS

The University of Tokyo, ...

1. A pharmaceutical composition, comprising one or more purified live bacterial strains belonging to Clostridium clusters IV or XIVa,wherein the one or more bacterial strains induces proliferation and/or accumulation of regulatory T cells,
wherein the one or more bacterial strains are isolated from a human, and
wherein the pharmaceutical composition is formulated for delivery to the intestine.
US Pat. No. 10,555,467

POLYNUCLEOTIDES AND KITS ASSOCIATED WITH SOYBEAN IRON DEFICIENCY TOLERANCE AND METHODS OF DETECTION AND BREEDING

PIONEER HI-BRED INTERNATI...

1. A method of detecting a first soybean plant or soybean germplasm with improved iron deficiency tolerance, the method comprising the steps of:(a) isolating nucleic acids from a population of soybean plants or soybean germplasm;
(b) detecting in the nucleic acids at least one favorable allele of one or more marker locus within a chromosomal interval flanked by and including Gm05:8808821-Gm05:9098413, wherein the one or more marker loci are selected from the group consisting of S29731 allele G, Gm05:9031274 allele G, Gm05:9032977 allele A, Gm05:9009488 allele G, Gm05:8897027 allele C, Gm05:8826919 allele T, Gm05:8912496 allele G, Gm05:8915863 allele C, Gm05:9011110 allele T, Gm05:9081402 allele G, Gm05:8912289 allele G, Gm05:8994830 allele C, Gm05:9098413 allele A, and Gm05:8808821 allele T; and
(c) selecting a first soybean plant based on the presence of the at least one favorable allele of the one or more marker locus;
(d) crossing the soybean plant selected in step (c) with a second plant not having said favorable allele of the one or more marker locus;
(e) collecting seeds from said cross; and
(f) growing a progeny soybean plant from said seed which comprises said favorable allele of the one or more marker locus, thereby producing a soybean plant with improved iron deficiency tolerance compared to a soybean plant not comprising said one or more markers in said chromosomal interval.
US Pat. No. 10,555,979

USE OF LACTOBACILLUS PARACASEI GMNL-653 FOR PREPARING FOR A COMPOSITION FOR ALLEVIATING AXILLARY OSMIDROSIS

GENMONT BIOTECH INCORPORA...

1. A method used for alleviating axillary osmidrosis, comprising administrating a probiotic composition, wherein the probiotic bacterial strain includes Lactobacillus paracasei GMNL-653 with the deposition number of CCTCC M 2016226.
US Pat. No. 10,557,005

PAINTED POLYOLEFIN ARTICLES

Dow Global Technologies L...

1. A painted article, comprising:a primer layer between a substrate and a paint layer, the substrate being the product of a substrate forming composition including at least 50 wt % of an olefin block copolymer, based on the total weight of the substrate forming composition, and a polypropylene polymer having a density from 0.89 g/cm3 and 0.92 g/cm3,
wherein the substrate is free of (1) phthalate-based plasticizer, (2) halogen-containing polymer, and (3) leachable, small polymeric units derived from styrene monomer, and
wherein the substrate forming composition comprises an alpha-olefin comonomer content of less than 9.7 mol %.
US Pat. No. 10,555,468

SOYBEAN VARIETY HLL0771

BASF AGRICULTURAL SOLUTIO...

1. A seed of soybean variety HLL0771, wherein a representative sample of seed of said soybean variety is deposited under ATCC Accession No. PTA-125952 .
US Pat. No. 10,555,980

TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION

Vedanta Biosciences, Inc....

1. A method to suppress an abnormal or excessive immune response comprising administering a pharmaceutical composition comprising a purified bacterial mixture consisting of 7 or more bacterial strains comprising 16S rDNA sequences of at least 97% sequence identity to nucleic acid sequences selected from the group consisting of SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21, to the subject in an amount sufficient to suppress the abnormal or excessive immune response.
US Pat. No. 10,555,469

SOYBEAN VARIETIES ‘2441083’, ‘2441085’, AND ‘2441246’

Asociados Don Mario S.A.,...

1. A soybean seed selected from the group consisting ofa soybean seed designated as ‘2441083’, representative sample of seed having been deposited under ATCC Accession Number PTA-125118;
a soybean seed designated as ‘2441085’, representative sample of seed having been deposited under ATCC Accession Number PTA-125119;
and a soybean seed designated as ‘2441246’, representative sample of seed having been deposited under ATCC Accession Number PTA-125120.
US Pat. No. 10,555,981

ONCOLYTIC VIRUS FOR EXPRESSION OF IMMUNE CHECKPOINT MODULATORS

Transgene S.A., Illkirch...

1. A method for treating a proliferative disease, comprising administering an oncolytic virus comprising inserted in its genome a nucleic acid molecule encoding one or more immune checkpoint modulator(s) wherein said virus is a vaccinia virus defective for Ribonucleotide reductase (RR) activity resulting from inactivating mutations in only the viral 14L gene and defective for thymidine kinase (TK) resulting from inactivating mutations in the J2R viral gene, wherein said one or more immune checkpoint modulator(s) is an antibody that specifically binds to PD-1 or a pharmaceutical composition comprising an effective amount of said oncolytic virus wherein said virus is a vaccinia virus defective for Ribonucleotide reductase (RR) activity resulting from inactivating mutations in only the viral 14L gene and defective for thymidine kinase (TK) resulting from inactivating mutations in the J2R viral gene, wherein said one or more immune checkpoint modulator(s) is an antibody that specifically binds to PD-1 and a pharmaceutical acceptable vehicle.
US Pat. No. 10,555,470

SOYBEAN CULTIVAR S160123

M.S. Technologies, L.L.C....

1. A plant of soybean cultivar S160123, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-25326.
US Pat. No. 10,555,982

COMPOSITION CONTAINING OROXYLIN A AND METHOD OF EXTRACTION THEREOF

SAMI LABS LIMITED, Banga...

1. A composition comprising 10%-15% w/w Oroxylin A, 10%-25% w/w Baicalein and 2%-10% w/w Chrysin, isolated from the bark of Oroxylum indicum.
US Pat. No. 10,555,471

SOYBEAN CULTIVAR S170082

M.S. Technologies, L.L.C....

1. A plant of soybean cultivar S170082, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-125454.
US Pat. No. 10,555,983

COMPOSITION FOR BRAIN ACTIVATION, COMPRISING GINSENG FRUIT EXTRACT

AMOREPACIFIC CORPORATION,...

1. A method for activating the brain or for improving cognitive function comprising: administering a ginseng fruit extract to activate the brain, to improve cognitive function to a subject having cognitive function disorders thereof,wherein the brain is activated or improves cognitive function in a subject in need, wherein the administration is administrating the effective amount of a ginseng fruit extract orally to a subject in need, and
wherein the ginseng fruit extract is an ethanol extract of the ginseng fruit which is prepared by adding ethanol to a ginseng fruit, followed by refluxing and filtering, and then concentrating under reduced pressure, and comprises 30 wt % or more of a crude saponin based on the total weight of the ginseng fruit extract,
wherein the cognitive function disorder is one or more selected from degenerative brain diseases, alcoholic cognitive function disorder, cognitive function disorder caused by cerebral hemorrhage, loss of brain function due to accidents, aging-induced cognitive function disorder, schizophrenia, and attention deficit hyperactivity disorder (ADHD).
US Pat. No. 10,559,828

SLURRY FOR LITHIUM ION SECONDARY BATTERY POSITIVE ELECTRODES

ZEON CORPORATION, Tokyo ...

1. A slurry for a lithium ion secondary battery positive electrode comprising a positive electrode active material, a binder, a conductive material, and N-methyl pyrrolidone, whereinsaid binder comprises a nitrile group containing acrylic polymer and a fluorine containing polymer,
a ratio of a viscosity measured by a coaxial cylinder type viscometer ((the viscosity at a shear speed of 2 sec?1)/(the viscosity at the shear speed of 20 sec?1)) is 1.0 to 2.5,
the viscosity at the shear speed of 2 sec?1 measured by a coaxial cylinder type viscometer is 1,000 to 20,000 mPa·s, and the viscosity at the shear speed of 20 sec?1 measured by a coaxial cylinder type viscometer is 1,000 to 8,000 mPa·s,
the fluorine containing polymer is polyvinylidene fluoride,
a weight average molecular weight of said nitrile group containing acrylic polymer is 100,000 to 2,000,000,
a content of said binder is 0.8 to 3 parts by weight with respect to 100 parts by weight of the positive electrode active material,
a content ratio of the nitrile group containing acrylic polymer in said binder is 5 to 50 wt %,
a content of said conductive material is 1 to 3 parts by weight with respect to 100 parts by weight of the positive electrode active material,
the nitrile group containing acrylic polymer contains 5 to 35 wt % of nitrile group containing monomer unit, and
both of the nitrile group containing acrylic polymer and the fluorine containing polymer are dissolved in N-methyl pyrrolidone.
US Pat. No. 10,555,472

INBRED CORN LINE IV7

Limagrain Europe S.A., S...

1. A seed of inbred corn line designated IV7, wherein a representative sample of seed of said line was deposited under ATCC Accession No. PTA 126032.
US Pat. No. 10,555,984

METHOD FOR INCREASING EXPRESSION OF PDPRD GENE BY USING PEANUT SKIN EXTRACT

TCI CO., LTD., Taipei (T...

1. A method for preventing or treating hepatocellular carcinoma, consisting of administrating to a subject in need an effective amount of a composition consisting of a peanut skin extract and a carrier, wherein the extract is obtained by extracting the peanut skin with water.
US Pat. No. 10,557,778

OPTICAL PROJECTION TOMOGRAPHY MICROSCOPY (OPTM) FOR LARGE SPECIMEN SIZES

1. A method to prepare a specimen of biological tissue for optical imaging, comprising:receiving a thin-needle core biopsy (TNCB) specimen of biological tissue, the TNCB specimen having an elongated shape;
preserving the elongated shape and integrity of the TNCB specimen during preparation of the TNCB specimen for optical imaging, said preparation including:
introducing the TNCB specimen into a specimen channel of a microfluidics device, the specimen channel structured to preserve the elongated shape and integrity of the TNCB specimen;
moving the TNCB specimen from the specimen channel into a specimen chamber of the microfluidics device while retaining the elongated shape and integrity of the TNCB specimen, wherein the specimen chamber is structured to preserve the elongated shape and integrity of the TNCB specimen; and
preparing the TNCB specimen within the specimen chamber for optical imaging such that the TNCB specimen will retain its elongated shape and integrity during said optical imaging.
US Pat. No. 10,555,473

PLANTS AND SEEDS OF CORN VARIETY CV579327

Monsanto Technology LLC, ...

1. A plant of corn variety CV579327, wherein representative seeds of corn variety CV579327 have been deposited under ATCC Accession No. PTA-125244.
US Pat. No. 10,559,831

EXOTHERMICALLY RESPONSIVE CATHODES AND METHODS OF PRODUCTION THEREOF

IH IP Holdings Limited, ...

1. A method of producing electrodes comprising:selecting a palladium alloy;
annealing the palladium alloy at a first temperature above 350° C.;
cold working the palladium alloy into a desired electrode shape;
annealing the palladium alloy at a second temperature and for a time sufficient to produce a grain size between about 5 microns and about 100 microns;
etching the palladium alloy;
rinsing the palladium alloy with at least one of water and heavy water; and
storing the palladium alloy in an inert environment.
US Pat. No. 10,555,474

PLANTS AND SEEDS OF CORN VARIETY CV674722

Monsanto Technology LLC, ...

1. A plant of corn variety CV674722, wherein representative seeds of corn variety CV674722 have been deposited under ATCC Accession No. PTA-125230.
US Pat. No. 10,555,986

DIETARY SUPPLEMENT DERIVED FROM NATURAL PRODCUTS BY HOT MELT EXTRUSION (HME) PROCESSING

1. A cocoa extract composition rich in flavonoids consisting essentially of a cocoa extract dispersed by hot melt extrusion or hot melt mixing and encapsulated in polymer matrices selected from the group consisting of:(i) a mixture of a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer with a copolymer of methacrylic acid and methyl methacrylate; and
(ii) a mixture of ethyl cellulose, polyvinyl acetate-polyvinylpyrrolidone copolymer and a copolymer of methacrylic acid and methyl methacrylate.
US Pat. No. 10,557,012

COATING COMPOSITION COMPRISING SUBMICRON CALCIUM CARBONATE

OMYA INTERNATIONAL AG, O...

1. A glossing and opacifying coating composition comprising:(i) at least one submicron ground natural calcium carbonate (SMGCC) having a volume median particle diameter d50 of 0.05 to 0.3 ?m and a d98 of less than or equal to 0.6 ?m, and titanium dioxide, wherein the titanium dioxide: SMGCC weight ratio in the composition is from 75:25 to 98:2, and wherein the calcium carbonate is calcite, marble, chalk or limestone; and
(ii) glossing and opacifying coating composition components,
wherein the glossing and opacifying coating composition has a pigment volume concentration (PVC) of from 5 vol.-% up to a critical pigment volume concentration (CPVC),and wherein the glossing and opacifying coating composition, applied to a contrast card to form a layer having a thickness of 150 ?m or 300 ?m, has a gloss that is within ±3% of the gloss of the same composition and thickness in which the SMGCC is fully replaced with the titanium dioxide, when gloss is measured either at a 60° or an 85° incident angle according to DIN 67530.
US Pat. No. 10,555,475

PLANTS AND SEEDS OF CORN VARIETY CV690087

Monsanto Technology LLC, ...

1. A plant of corn variety CV690087, wherein representative seeds of corn variety CV690087 have been deposited under ATCC Accession No. PTA-125238.
US Pat. No. 10,555,987

GHRH AGONISTS FOR THE TREATMENT OF ISCHEMIC DISORDERS

UNIVERSITY OF MIAMI, Mia...

1. A method of promoting vasculogenesis in a subject, the method comprising administering a therapeutically effective amount of a GHRH agonist peptide to the subject, wherein the GHRH agonist peptide is P-27409 [N-Me-Tyr1, D-Ala2, Orn12, Abu15, Orn21, Nle27, Asp28]hGHRH(1-29)NH—CH3 or a pharmaceutically acceptable salt of the foregoing.
US Pat. No. 10,557,013

COATING COMPOSITION COMPRISING SUBMICRON CALCIUM CARBONATE AND USE THEREOF

OMYA INTERNATIONAL AG, O...

1. Concrete, wood, paper, metal or board coated with a glossing and opacifying coating composition comprising:(i) at least one submicron ground natural calcium carbonate (SMGCC) having a volume median particle diameter d50 of 0.05 to 0.3 ?m and a d98 of less than or equal to 0.6 ?m, and titanium dioxide, wherein the titanium dioxide:SMGCC weight ratio in the composition is from 75:25 to 98:2, and wherein the calcium carbonate is calcite, marble, chalk or limestone; and
(ii) glossing and opacifying coating composition components,
wherein the glossing and opacifying coating composition has a pigment volume concentration (PVC) of from 5 vol.-% up to a critical pigment volume concentration (CPVC),
and wherein the glossing and opacifying coating composition, applied to a contrast card to form a layer having a thickness of 150 ?m or 300 ?m, has a gloss that is within ±3% of the gloss of the same composition and thickness in which the SMGCC is fully replaced with the titanium dioxide, when gloss is measured either at a 60° or an 85° incident angle according to DIN 67530.
US Pat. No. 10,555,476

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH265634

Monsanto Technology LLC, ...

1. A seed of hybrid corn variety CH265634, produced by crossing a first plant of variety CV292720 with a second plant of variety CV744222, wherein representative seeds of said varieties CV292720 and CV744222 are deposited under ATCC Accession Nos. PTA-9834 and PTA-124496, respectively.
US Pat. No. 10,555,988

ANTIMICROBIAL PEPTIDES, THEIR VARIANTS AND USES

Chain Antimicrobials Oy, ...

1. An antimicrobial peptide, comprising any one of synthetically prepared SEQ ID NOs: 55, 58, 59 and 61 to 65 peptide or said antimicrobial peptide defined by a peptide sequence having at least 90 identity to any one of SEQ ID NOs: 55, 58, 59 and 61 to 65.
US Pat. No. 10,555,477

SOYBEAN VARIETY 5PTAY19

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PTAY19, representative seed of the variety having been deposited under ATCC Accession Number PTA-126221.
US Pat. No. 10,555,989

TREATMENT OF LEARNING DISABILITIES AND OTHER NEUROLOGICAL DISORDERS WITH SK CHANNEL INHIBITOR(S)

1. A method for treating a learning disability in a subject exposed to alcohol in utero or in a subject having fetal alcohol syndrome comprising administering tamapin or a tamapin analog to a subject in need thereof.
US Pat. No. 10,557,015

EPOXY RESIN-EPOXY CURING SYSTEMS WITH A LATENT THICKENING TENDENCY

BYK-Chemie GmbH, Wesel (...

1. An adhesive, sealant, a coating material or a molding compound obtained from a two-component or multicomponent system comprisingat least one epoxy resin component 1 which comprises
i. at least one epoxy resin,
ii. at least one inorganic thickener (a1), and
iii. at least one wetting and dispersing agent (a2) which inhibits the thickening effect of the inorganic thickener (a1);witha curing agent component 2 which comprises
i.) at least one component (b1) which at least partly eliminates the inhibition of the thickening effect of the inorganic thickener (a1);
the wetting and dispersing agent (a2) being nonreactive toward the at least one epoxy resin and the curing agent component 2 being reactive toward the epoxy resin component 1;
wherein the at least one component (b1) is a polymer;
wherein in the resulting mixture of the epoxy resin component 1 and the curing agent component 2 the weight ratio of wetting and dispersing agent (a2) to component (b1) is 15:1 to 1:5;
wherein the curing agent component 2 comprises a curing agent different from and in addition to the at least one component (b1), said curing agent employed substantially stoichiometrically relative to the at least one epoxy resin; and
wherein the at least one epoxy resin component 1 and the curing agent component 2 of the two-component or multicomponent system represent two spatially separate individual components stored separately before mixing.
US Pat. No. 10,555,478

SOYBEAN CULTIVAR 75242840

M.S. Technologies, L.L.C....

1. A plant of soybean cultivar 75242840, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-125325.
US Pat. No. 10,555,990

MESENCHYMAL STEM CELL DIFFERENTIATION

NOVARTIS AG, Basel (CH) ...

1. A polypeptide consisting of an amino acid sequence as set forth in any one of SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7, wherein said polypeptide is PEGylated.
US Pat. No. 10,555,479

SOYBEAN CULTIVAR 71342318

M.S. Technologies, L.L.C....

1. A plant of soybean cultivar 71342318, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-125347.
US Pat. No. 10,555,991

ONE COMPONENT FIBRIN GLUE COMPRISING ZYMOGENS

Omrix Biopharmaceuticals ...

1. A method for preparing a sealant at a surface comprising:(i) providing a sealant formulation comprising fibrinogen; vitamin K-dependent clotting zymogens comprising at least Factor II and Factor X; and at least one reversible inhibitor of at least one of the vitamin K-dependent clotting zymogens, wherein the sealant formulation is free of an added irreversible thrombin inhibitor; and wherein the vitamin K-dependent clotting zymogens are provided as a concentrate, concentrated by about 2- to 50-fold compared to their concentration in plasma, as normalized to Factor II and (ii) applying the formulation to the surface under conditions which facilitate fibrin polymerization at the surface.
US Pat. No. 10,555,480

SOYBEAN VARIETY 01068350

Monsanto Technology LLC, ...

1. A plant of soybean variety 01068350, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-125716.
US Pat. No. 10,555,992

IMMUNOGENIC PROTEINS AGAINST CLOSTRIDIUM DIFFICILE

University of South Flori...

1. An immunogenic protein comprising:i) a glucosyltransferase domain of Clostridium difficile toxin TcdB;
ii) a cysteine proteinase domain of Clostridium difficile toxin TcdB; and
iii) a receptor binding domain of Clostridium difficile toxin TcdA,
wherein the cysteine proteinase domain of Clostridium difficile toxin TcdB comprises a C698A amino acid substitution when compared to SEQ ID NO.: 8, and wherein the immunogenic protein lacks a transmembrane domain.
US Pat. No. 10,557,018

THREE-DIMENSIONAL OBJECT FORMING LIQUID, THREE-DIMENSIONAL OBJECT FORMING LIQUID SET, THREE-DIMENSIONAL OBJECT PRODUCING METHOD, AND THREE-DIMENSIONAL OBJECT

Ricoh Company, Ltd., Tok...

1. A three-dimensional object forming liquid,wherein the three-dimensional object forming liquid is a hydrogel precursor that comprises a multifunctional monomer, and
wherein a viscosity of the three-dimensional object forming liquid is from 3 mPa·s to 20 mPa·s at 25° C., and an 80% strain compressive stress of a hydrogel obtained by curing the three-dimensional object forming liquid is 0.4 MPa or greater.
US Pat. No. 10,555,481

SOYBEAN VARIETY 01068364

Monsanto Technology LLC, ...

1. A plant of soybean variety 01068364, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-125717.
US Pat. No. 10,555,993

DIMETHYL FUMARATE AND VACCINATION REGIMENS

Biogen MA Inc., Cambridg...

1. A method of treating multiple sclerosis in a human subject in need thereof, said method comprising:(a) administering to the subject a first dose of a pharmaceutical composition for a first dosing period, wherein the pharmaceutical composition comprises a fumarate agent selected from the group consisting of monomethyl fumarate, a pharmaceutically acceptable salt of monomethyl fumarate, dimethyl fumarate, and a combination thereof;
(b) administering a vaccine to the subject, wherein the subject receives the vaccine during the first dosing period; and
(c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period, wherein: (i) the second dosing period is after the first dosing period, and (ii) the second dosing period is initiated within one day of the end of the first dosing period;
wherein the second dose is the same as the first dose, and the first dose and the second dose are administered daily;
wherein the multiple sclerosis is a relapsing form of multiple sclerosis;
wherein the first dose is a therapeutically effective amount of monomethyl fumarate, a pharmaceutically acceptable salt of monomethyl fumarate, dimethyl fumarate, or a combination thereof; and
wherein the vaccine induces (a) a T cell-dependent anamnestic humoral immune response, (b) a T cell-dependent neoantigen immune response, or (c) a T cell-independent immune response.
US Pat. No. 10,556,251

METHOD OF COATING METALLIC SURFACE WITH COATING HAVING IMPROVED SAG RESISTANCE

The Sherwin-Williams Comp...

1. A method of coating a metallic surface of an article, comprising the step of applying onto at least a portion of the substrate having a metallic surface under conditions effective to form a coating, a coating system comprising:a. an aqueous coating composition, comprising
i. an aqueous carrier;
ii. a resin component in admixture with the aqueous carrier; and
iii. one or more CAS agents dispersed in the aqueous coating composition, wherein the one or more CAS agents are present in an amount greater than 0.12 kg per 100 L of the aqueous coating composition,wherein the aqueous coating composition has a pH of less than 6.
US Pat. No. 10,555,482

SOYBEAN VARIETY 01068427

Monsanto Technology LLC, ...

1. A plant of soybean variety 01068427, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-125718.
US Pat. No. 10,555,994

PCV2 ORF2 CARRIER PLATFORM

1. A recombinant polypeptide selected from the group consisting of:a) a PCV2 ORF2 protein characterized in that at least one amino acid residue in the BC loop is replaced by an amino acid sequence of interest;
b) a PCV2 ORF2 protein characterized in that an amino acid sequence of interest is inserted into the BC loop; or
c) a combination of a) and b);wherein the amino acid sequence of interest comprises SEQ ID NO: 5 or 7.
US Pat. No. 10,555,483

SOYBEAN VARIETY 01067598

Monsanto Technology LLC, ...

1. A plant of soybean variety 01067598, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-125765.
US Pat. No. 10,557,021

ARTIFICIAL TIMBER AND METHOD FOR PREPARING ARTIFICIAL TIMBER

1. A method for preparing an artificial timber, comprising steps of:(1) dissolving 15 to 35 parts by weight of lignin, 35 to 50 parts by weight of cellulose and 20 to 35 parts by weight of hemicellulose to form a lignocellulose, and
adding the lignocellulose into an ionic liquid, and heating and stirring for dissolving to obtain a lignocellulose ionic liquid dispersion;
(2) cleaning and replacing the ionic liquid with water to obtain a lignocellulose hydrogel; and
(3) drying the lignocellulose hydrogel to obtain an artificial timber.
US Pat. No. 10,555,484

SOYBEAN VARIETY 01068903

Monsanto Technology LLC, ...

1. A plant of soybean variety 01068903, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-125719.
US Pat. No. 10,555,996

THERAPEUTIC HPV16 VACCINES

1. A recombinant pox virus vector comprising a nucleic acid sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:1, wherein the nucleic acid sequence is operably linked to a promoter.
US Pat. No. 10,555,485

SOYBEAN VARIETY 01073532

Monsanto Technology LLC, ...

1. A plant of soybean variety 01073532, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-125724.
US Pat. No. 10,557,023

CABLE INSULATION COMPRISING A BLEND OF LDPE AND POLYPROPYLENE

Dow Global Technologies L...

1. A composition comprising, in weight percent based on the weight of the composition:(A) 85 to 99% low density polyethylene (LDPE) having a crystallinity of greater than 40%;
(B) 1 to less than 14% propylene polymer having an upper melting point of greater than or equal to (?) 130° C.; and
(C) ?0.5% peroxide.
US Pat. No. 10,555,486

SOYBEAN VARIETY 01068910

Monsanto Technology LLC, ...

1. A plant of soybean variety 01068910, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-125731.
US Pat. No. 10,555,998

INACTIVATED EQUINE INFLUENZA VIRUS VACCINES

Intervet Inc., Madison, ...

1. An isolated equine influenza virus (EIV) isolate comprising a genome that encodes a hemagglutinin protein (HA) comprising an amino acid sequence that comprises 95% or greater identity with the amino acid sequence of SEQ ID NO: 2; wherein the amino acid sequence of the HA:comprises an amino acid residue at position 222 other than that of a tryptophan or an arginine, and either an amino acid residue at position 223 other than that of a valine, or an amino acid residue at position 188 other than that of an asparagine; or
comprises an amino acid residue at position 222 other than that of a tryptophan or an arginine, an amino acid residue at position 223 other than that of a valine, and an amino acid residue at position 188 other than that of an asparagine;
wherein said EIV has been inactivated through being killed in an unnatural manner.
US Pat. No. 10,556,256

ANTIBACTERIAL WATER

TAKEDA PHARMACEUTICAL COM...

6. A method of producing nano-bubble water comprising not less than 2.0×108 bubbles/mL of nanobubbles, comprising forcedly dissolving a gas in the presence of polysorbate 80 and/or poly(vinyl alcohol) in a pressurized container, flashing the gas into nano-bubble water through a nozzle, whereby the gas is supersaturated by depressurization and released as a mixture of micro-bubbles or nano-bubbles in the nano-bubble water, and allowing the micro-bubbles to naturally float and be released from the nano-bubble water, to produce the nano-bubble water comprising not less than 2.0×108 bubbles/mL of nanobubbles.
US Pat. No. 10,555,487

SOYBEAN VARIETY 01067694

Monsanto Technology LLC, ...

1. A plant of soybean variety 01067694, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-125772.
US Pat. No. 10,555,999

INFLUENZA VACCINE

GLAXOSMITHKLINE BIOLOGICA...

1. A method for immunizing a human against influenza virus infection, the method comprising:selecting a human who was previously vaccinated with a monovalent first vaccine composition comprising a low amount of an influenza virus haemagglutanin (HA) antigen from an influenza virus of subtype H2, H5, H6, H7 or H9, in combination with an adjuvant, wherein the low HA antigen amount does not exceed 15 ?g of HA antigen per dose, and wherein said adjuvant is an oil-in-water emulsion comprising squalene and an emulsifying agent; and
administering to the selected human a monovalent second vaccine composition comprising a low amount of an influenza virus HA antigen from a variant of the same influenza virus subtype, in combination with an adjuvant, wherein the low HA antigen amount does not exceed 15 ?g of HA antigen per dose, wherein said adjuvant is an oil-in-water emulsion comprising squalene and an emulsifying agent; and wherein the variant comprises an antigenically distinct HA.
US Pat. No. 10,557,025

POLYPROPYLENE CAP OR FILM COMPOSITION

FINE ORGANICS INDUSTRIES ...

1. A polypropylene cap composition, comprising(i) at least 94% by weight of polypropylene, and
(ii) 0.05% to 1.0% by weight of a slip and/or an anti-blocking agent;
 wherein the slip and/or anti-blocking agent comprises 25% by weight behenamide and 75% by weight distilled glycerol monostearate of 90% purity.
US Pat. No. 10,555,488

SOYBEAN VARIETY 01067714

Monsanto Technology LLC, ...

1. A plant of soybean variety 01067714, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-125773.
US Pat. No. 10,556,000

THERMOSTABLE SPRAY DRIED ROTAVIRUS VACCINE FORMULATION AND PROCESS THEREOF

MSD WELLCOME TRUST HILLEM...

1. A thermostable spray dried rotavirus vaccine formulation comprising:at least one rotavirus serotype
a sugar, a buffering agent, a structural stabilizer, a salt, a bulking agent, and an activating agent,
wherein
the sugar is trehalose or sucrose or a combination thereof at 1-15% (w/v);
the buffering agent is HEPES or histidine or a combination thereof at 10-100 mM;
the structural stabilizer is Ca2+ at 0.1-5 mM;
the salt is sodium chloride at 0.88% (w/v);
the bulking agent is maltodextrin at 0.5-10% (w/v); and
the activating agent is glutamic acid at 0.131% (w/v);and wherein the spray dried formulation exhibits potency losses of less than Log 10=[0.5] when stored at 37° C. for 4 weeks.
US Pat. No. 10,557,026

COMPOSITION COMPRISING POLYPROPYLENE, POLYETHYLENE, AND A COMPATILIZER

SABIC GLOBAL TECHNOLOGIES...

1. A composition comprising polypropylene, polyethylene and a compatibiliser, wherein said compatibiliser is a non-aromatic polyester having an average M/E ratio of at least 10, wherein M is the number of backbone carbon atoms in the polyester not including the carbonyl carbons and E is the number of ester groups in the polyester.
US Pat. No. 10,555,489

SOYBEAN VARIETY 01068972

Monsanto Technology LLC, ...

1. A plant of soybean variety 01068972, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-125877.
US Pat. No. 10,556,001

THERMAL INACTIVATION OF ROTAVIRUS

The united States of Amer...

1. A method of inducing an immune response to rotavirus in a subject, comprising:administering to the subject a therapeutically effective amount of a vaccine composition, wherein the vaccine composition comprises:
a) an antigenic thermally-inactivated rotavirus that has a substantially intact rotavirus particle structure, wherein the substantially intact rotavirus particle structure is triple-layer rotavirus particles, double-layer rotavirus particles, or a combination of triple-layer rotavirus particles and double-layer rotavirus particles, and wherein the antigenic thermally-inactivated rotavirus is produced by the process of
suspending isolated rotavirus particles in an aqueous buffer, the aqueous buffer having an osmolality in the range of about 200-500 mOsm, comprising a concentration of a salt of a divalent cation in the range of about 1 mM-15 mM and an amount of a sugar and/or sugar alcohol in the range of about 1-20% w/v to produce a starting preparation of rotavirus particles having an intact rotavirus particle structure;
exposing the starting preparation of rotavirus particles to a temperature in the range of about 50° C.-73° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection, wherein the incubation time is in the range of about 30 minutes to 24 hours inclusive, thereby producing the thermally-inactivated rotavirus;
b) an adjuvant; and
c) a sterile pharmaceutically acceptable carrier,
thereby inducing the immune response to the rotavirus in the subject.
US Pat. No. 10,557,027

HIGH FLOW TPO COMPOSITION WITH EXCELLENT TENSILE STRAIN AT BREAK AND LOW POWDER STICKINESS

Borealis AG, Vienna (AT)...

1. A heterophasic propylene copolymer (HECO) comprisinga) a propylene homopolymer (HPP) having a melt flow rate MFR2 (230° C.) measured according to ISO 1133 in the range of 100 to 300 g/10 min, and
b) an elastomeric propylene-ethylene copolymer (E),
wherein the heterophasic propylene copolymer (HECO)
(i) has a melt flow rate MFR2 (230° C.) measured according to ISO 1133 in the range of 20 to 35 g/10 min,
(ii) comprises a xylene cold soluble (XCS) fraction in an amount from 28 to 38 wt.-%, based on the total weight of the heterophasic propylene copolymer (HECO),
wherein further the xylene cold soluble (XCS) fraction of the heterophasic propylene copolymer (HECO) has
(iii) an intrinsic viscosity (IV) in the range of 2.5 to 3.5 dl/g, and
(iv) an ethylene content (EC) of 15 to 35 wt.-% based on the total weight of the xylene cold soluble (XCS) fraction of the heterophasic propylene copolymer (HECO).
US Pat. No. 10,555,490

SOYBEAN CULTIVAR 85370909

Monsanto Technology LLC, ...

1. A plant of soybean cultivar 85370909, representative seed of said soybean cultivar having been deposited under NCMA Accession No. 201909031.
US Pat. No. 10,556,002

DUAL ANTHRAX-PLAGUE VACCINES THAT CAN PROTECT AGAINST TWO TIER-1 BIOTERROR PATHOGENS, BACILLUS ANTHRACIS AND YERSINIA PESTIS

The Catholic University o...

1. An immunogenic composition comprising one or more bacteriophage nanoparticles arrayed with one or more Soc fusion proteins on capsid surface of each bacteriophage nanoparticle, wherein the one or more Soc fusion proteins comprises a Soc fused to an antigen selected from the group consisting of a mutated F1 antigen from Yersinia pestis, a V antigen from Yersinia pestis, a protective antigen (PA) from B. anthracis, and combination thereof:wherein the one or more Soc fusion proteins comprise a recombinant protein FlmutV-Soc that comprises a mutated F1 antigen, a V antigen, and a Soc;
wherein the mutated F1 antigen is fused in-frame to the N-terminus of a V antigen and the V antigen is fused in-frame to N-terminus of a Soc;
wherein the one or more Soc fusion proteins comprise a recombinant protein Soc-PA that comprises a Soc fused in-frame to the N-terminus of PA; and
wherein the recombinant protein FlmutV-Soc and the recombinant protein Soc-PA are separately arrayed on different capsid of bacteriophage nanoparticle; and wherein the immunogenic composition comprising a 1:1 mixture of bacteriophage nanoparticles separately displaying FlmutV-Soc and Soc-PA.
US Pat. No. 10,555,491

SOYBEAN CULTIVAR 83072718

Monsanto Technology LLC, ...

1. A plant of soybean cultivar 83072718, representative seed of said soybean cultivar having been deposited under NCMA Accession No. 201909029.
US Pat. No. 10,557,797

METHOD TO DETECT BERYLLIUM BY OPTICAL FLUORESCENCE

AJJER L.L.C., Tucson, AZ...

1. A method of determining a presence or an amount of beryllium or beryllium compound in a sample comprising:(a) extracting the beryllium or the beryllium compound from the sample into a liquid medium unless the sample itself is a liquid medium;
(b) combining the liquid medium comprising the beryllium or the beryllium compound with a second solution creating a mixture, wherein the second solution contains a fluorescent indicator and a pH of the second solution is greater than 12.9 and;
(c) measuring optical fluorescence of the mixture, and correlating the optical fluorescence of the mixture with the presence or the amount of the beryllium or the beryllium compound within said mixture wherein the second solution with the fluorescent indicator contains no buffer.
US Pat. No. 10,555,492

SOYBEAN CULTIVAR 81430038

Monsanto Technology LLC, ...

1. A plant of soybean cultivar 81430038, representative seed of said soybean cultivar having been deposited under NCMA Accession No. 201909019 .
US Pat. No. 10,556,004

IMMUNOPOTENTIATOR

TORAY INDUSTRIES, INC., ...

1. A method for immunopotentiation, comprising administering in vivo an immunopotentiator as an active ingredient to an organism or a subject,wherein the immunopotentiator comprises, as an active ingredient, a modified ?-glucan in which ?-glucan having immunopotentiating effect and poly(hydroxy acid) are covalently bonded, and
wherein ?-glucan is a polymer of glucose linked by at least one ?-1,3 bond and/or at least one ?-1,6 bond.
US Pat. No. 10,557,030

PLASTICIZED PVC ADMIXTURES WITH SURFACE MODIFYING MACROMOLECULES AND ARTICLES MADE THEREFROM

Evonik Canada Inc., Burl...

1. A blended composition comprising from 50% to 99.9% (w/w) of a polyvinyl chloride base polymer, from 10% to 50% (w/w) of a plasticizer that is di-(2-ethylhexyl)phthalate (DEHP), and from 0.01% to 20% (w/w) of a surface modifying macromolecule (SMM) described by the formula:FT-[B-A]n-B-FT,
where
(i) A comprises poly(diethylene glycol)adipate, (neopentyl glycol-ortho phthalic anhydride) polyester, (diethylene glycol-ortho phthalic anhydride) polyester, (1,6-hexanediol-ortho phthalic anhydride) polyester, polypropylene oxide, polyethylene oxide, or polytetramethylene oxide;
(ii) B comprises a urethane;
(iii) FT is a polyfluoroorgano group, and
(iv) n is an integer from 1 to 10.
US Pat. No. 10,559,850

NONAQUEOUS ELECTROLYTE COMPOSITIONS COMPRISING CYCLIC SULFATES

Solvay SA, Brussels (BE)...

1. An electrolyte composition comprising:a) an organic carbonate selected from ethylene carbonate and/or propylene carbonate;
b) a fluorinated acyclic carboxylic acid ester selected from CH3—COO—CH2CF2H;
c) a cyclic sulfate selected from one of ethylene sulfate or propylene sulfate; and
d) at least one electrolyte salt;
wherein the electrolyte composition comprises about 0.5 weight percent to about 3 weight percent of the cyclic sulfate.
US Pat. No. 10,555,493

ALFALFA VARIETY R410A109

Forage Genetics Internati...

1. A seed of alfalfa variety R410A109, wherein representative seed of said alfalfa variety have been deposited under ATCC Accession No. PTA-125605.
US Pat. No. 10,557,031

COMPOSITION INCLUDING AMORPHOUS FLUOROPOLYMER AND FLUOROPLASTIC PARTICLES AND METHODS OF MAKING THE SAME

3M Innovative Properties ...

1. A composition comprising:fluoroplastic particles having a mean particle size of less than 500 nanometers; and
an amorphous fluoropolymer comprising at least one of:
a segment represented by formula
—CF(Rf)—(CX2)n—(CX2CXR)m—O—R?f—Ok—(CXR?CX2)p—(CX2)q—CF(R?f)—
or a terminal segment represented by formula
Rf—CF(I)—(CX2)n—(CX2CXR)m—O—R?f—Ok—(CXR?CX2)p—(CX2)q—CF(R?f)—,
wherein
each X is independently F, H, or Cl;
Rf and R?f are each independently F or a monovalent perfluoroalkyl having 1 to 3 carbon atoms;
R and R? are each independently F or a partially fluorinated or perfluorinated alkyl having 1 to 3 carbons atoms;
R?f is a divalent fluoroalkylene having 1 to 8 carbon atoms or a divalent fluorinated alkylene ether having 1 to 20 carbon atoms and at least one ether linkage;
k is 0 or 1; and n, m, p, and q are each independently an integer from 0 to 5, with the proviso that when k is 0, n+m is at least 1 and p+q is at least 1, and wherein the amorphous fluoropolymer is a fluoroelastomer gum.
US Pat. No. 10,555,494

ALFALFA VARIETY R410A131

Forage Genetics Internati...

1. A seed of alfalfa variety R410A131, wherein representative seed of said alfalfa variety have been deposited under ATCC Accession No. PTA-125606.
US Pat. No. 10,556,006

COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE

TAIGA BIOTECHNOLOGIES, IN...

1. A method of treating a viral infection, comprising administering to an individual in need thereof a fusion peptide comprising:a. a transporter peptide sequence; and
b. a MYC polypeptide sequence,wherein the transporter peptide sequence transports the fusion peptide into the nucleus of an immune cell in the individual.
US Pat. No. 10,557,032

COMPOSITION FOR SUPPORT MATERIAL AND INK SET FOR STEREOLITHOGRAPHY

MAXELL HOLDINGS, LTD., K...

1. A composition for a support material to be used in a support material for supporting a model material used to form a shaped article through ink-jet stereolithography, the composition comprising:polyalkylene glycol having an oxybutylene group,
wherein a content of the polyalkylene glycol having an oxybutylene group is 15 parts by mass or more and 75 parts by mass or less with respect to a total mass of the composition for a support material taken as 100 parts by mass.
US Pat. No. 10,555,495

ALFALFA VARIETY R410A136

Forage Genetics Internati...

1. A seed of alfalfa variety R410A136, wherein representative seed of said alfalfa variety have been deposited under ATCC Accession No. PTA-125607.
US Pat. No. 10,556,007

ANTIBODY WHICH BINDS LRG1 AND METHODS OF USE

UCL Business LTD, London...

1. An antibody or fragment thereof that specifically binds to human Lrg1 and which comprises CDRs of SEQ ID NOs: 21, 22, 23, 24, 25, and 26.
US Pat. No. 10,557,033

RESIN COMPOSITION SUITABLE FOR RIGID-FLEX BOARD AND USE THEREOF

ELITE MATERIAL CO., LTD.,...

1. A prepreg for connecting a rigid board and a flexible board, comprising a reinforcement material and an insulation material covering the reinforcement material, the insulation material being formed by baking a resin composition to a semi-cured stage, the resin composition comprising 100 parts by weight of an epoxy resin, 5 to 15 parts by weight of a high molecular weight polyetheramine and 3 to 10 parts by weight of an amine-terminated acrylonitrile rubber,wherein the prepreg has a dust weight loss of less than or equal to 0.2%; and
wherein a laminate made from the prepreg has the following properties: a peel strength at 280° C. as measured by reference to IPC-TM-650 2.4.8 of greater than or equal to 5.3 lb/in; and a peel strength at room temperature as measured by reference to IPC-TM-650 2.4.8 of greater than or equal to 6.8 lb/in.
US Pat. No. 10,555,496

ALFALFA VARIETY R410M327

Forage Genetics Internati...

1. A seed of alfalfa variety R410M327, wherein representative seed of said alfalfa variety have been deposited under ATCC Accession No. PTA-125608.
US Pat. No. 10,556,008

METHODS OF TREATMENT OF KELOID USING AN ANTI-VEGF AGENT

1. A method for treating keloid recurrence, the method comprising administering a therapeutically effective amount of (1) an anti-VEGF antibody, (2) an anti-inflammatory steroid, and (3) a non-steroidal anti-inflammatory drug (NSAID) to a site where a keloid has been removed from a subject, wherein the anti-inflammatory steroid is alclometasone, diflorasone, fluocinonide, or prednicarbate, and the NSAID is diclofenac.
US Pat. No. 10,557,034

IONIZING-RADIATION-RESISTANT POLYCARBONATE RESIN COMPOSITION, AND MOLDED PRODUCT COMPRISING SAME

Lotte Advanced Materials ...

1. A polycarbonate resin composition comprising:about 100 parts by weight of a polycarbonate resin;
about 0.001 to about 5 parts by weight of a polyalkylene glycol;
about 0.001 to about 3 parts by weight of an epoxy ester compound containing an ester group and an epoxy group; and
about 0.01 to about 5 parts by weight of a halogenated polycarbonate oligomer.
US Pat. No. 10,555,497

PEPPER HYBRID DRPB2628 AND PARENTS THEREOF

Seminis Vegetable Seeds, ...

1. A pepper plant comprising at least a first set of the chromosomes of pepper line SBY-XD15-0123GMS, a sample of seed of said line having been deposited under ATCC Accession Number PTA-125003.
US Pat. No. 10,556,009

ANTI-BLYS ANTIBODY FORMULATIONS AND METHODS OF TREATMENT USING THEM

GlaxoSmithKline Intellect...

1. A pharmaceutical formulation for an antigen binding protein comprising:a. 200±20 mg/mL of the antigen binding protein;
b. about 5-15 mM of a buffering agent which is histidine providing a pH of 6.0±0.5;
c. about 115+10 mM of a tonicity agent which is sodium chloride;
d. about 20-30 mM of a stabilizer which is arginine; and
e. about 0.005 to 0.015% (w/v) of a nonionic surfactant which is polysorbate 80;wherein the antigen binding protein comprises amino acid sequences CDRH1 of SEQ ID NO:11, CDRH2 of SEQ ID NO: 12, CDRH3 of SEQ ID NO:13, CDRL1 of SEQ ID NO:14, CDRL2 of SEQ ID NO:15, and CDRL3 of SEQ ID NO:16.
US Pat. No. 10,557,035

RESIN COMPOSITION FOR HIGH FREQUENCY ELECTRONIC COMPONENTS

SABIC Global Technologies...

1. A resin composition comprising:(a) 40-90% by weight of a poly(arylene ether);
(b) 0-40% by weight of high-impact polystyrene (HIPS) and 0-40% by weight of general-purpose polystyrene (GPPS), provided that the HIPS, the GPPS, or the combination thereof represents 5-40% by weight of said composition;
(c) 5-25% by weight of an impact modifier; and,
(d) 15-400% by weight of a ceramic filler, as measured per 100 parts by weight of components (a)-(c),
wherein components (a)-(c) are each expressed relative to the total weight of components (a)-(c), and
wherein the resin composition exhibits a Df value of 8.7 e-4 to 1.2 e-3 when evaluated at 1.1 GHz using a split post dielectric resonator on a minimum sample size of 120 millimeter (mm) by 120 mm and a maximum sample thickness of 6 mm.
US Pat. No. 10,556,010

NEOADJUVANT THERAPY FOR BLADDER CANCER

PHOTOCURE ASA, Oslo (NO)...

1. A method of neoadjuvant therapy for muscular invasive bladder cancer (MIBC) or non-muscular invasive bladder cancer (NMIBC) with a high risk of progression in a bladder cancer patient who is scheduled for a cystectomy, said method of neoadjuvant therapy comprises:instilling into the bladder of said patient who is scheduled for a cystectomy a composition comprising hexyl 5-ALA ester (HAL) or a pharmaceutically acceptable salt thereof; and
exposing the inside of said bladder to light from a cystoscope;wherein the time between said neoadjuvant therapy and the cystectomy is zero to 6 weeks.
US Pat. No. 10,557,036

METAL-BASED HYDROGEN SULFIDE SCAVENGER AND METHOD OF PREPARING SAME

BAKER HUGHES, A GE COMPAN...

1. A composition comprising: asphalt or asphalt mix; and a dispersion of a hydrogen sulfide scavenger in an organic solvent, wherein the dispersion further comprises an organoclay suspension agent and an emulsifier, and wherein the proportion of the hydrogen sulfide scavenger is between 0.01% and 5% by weight with respect to the total weight of the asphalt composition.
US Pat. No. 10,556,011

METHOD AND SYSTEM FOR ADDING SENSORY CONDITIONING CUES IN A PHARMACOTHERAPEUTIC REGIMEN

1. An opioid administration kit, comprising:a sequential order of medicine amounts, wherein each said medicine amount in the sequential order is in a unitary form and includes a dose of at least one opioid and an amount of at least one non-active pharmacological agent (NPA), wherein the amount of NPA is configured to provide at least one non-visual sensory cue; and
wherein the opioid dose in each medicine amount within the sequential order is greater than the dose of opioid contained within the next medicine amount within the sequential order, and each medicine amount in the sequential order contains substantially the same amount of the NPA, and wherein the opioid dose in each medicine amount is a prescription drug; and
packaging configured to hold the medicine amounts and indicate the sequential order of the medicine amounts.
US Pat. No. 10,557,037

COATED PIGMENTS, METHOD FOR THE PRODUCTION AND THE USE THEREOF, COATING AGENT AND ARTICLE

ECKART GMBH, Hartenstein...

1. A pigment comprising a metallic substrate and at least one inorganic/organic hybrid layer,wherein the inorganic/organic hybrid layer comprises at least one metal oxide, at least one network former, and at least one organic polymer,
wherein the at least one metal oxide does not constitute an oxidation product of the metallic substrate, and the term “metal oxide” comprises oxides, hydroxides, and oxide hydrates of the metals and semimetals,
wherein the network former is joined at least partially covalently to the metal oxide and to the organic polymer,
wherein the ratio of the amount of metal oxide of the inorganic/organic hybrid layer to the specific surface area of the uncoated metal pigment is in a range from 16.1 mg/m2 to 25 mg/m2, and
the ratio of the amount of organic polymer of the inorganic/organic hybrid layer to the specific surface area of the uncoated metal pigment is in a range from 3.9 mg/m2 to 10.1 mg/m2.
US Pat. No. 10,557,038

EROSION RESISTANT COATINGS

Hontek Corporation, Sout...

1. An erosion resistant article comprising an airfoil shaped substrate having a leading edge surface exposed in use to high speed impingement of liquid or solid particles, said leading edge surface covered with a protective coating comprising: a polyurethane or polyurea coating selected from the group consisting of an isocyanate-terminated prepolymer cured with a curing agent, a polyisocyanate cured with a curing agent, and a water dispersion of a pre-reacted polyurethane, said curing agent selected from a group consisting of an aldimine, a ketimine, a polyaspartic ester, a polyamine, one or more polyols and mixtures thereof having a tensile strength greater than 1000 psi (70 kg/cm2), an elongation at break greater than 350%, a tensile set of less than 150%, and a Shore A hardness of 44 A to 95 A as measured at 68° F. when tested without any filler.
US Pat. No. 10,557,039

COMPOSITIONS COMPRISING BISPHOSPHONIC COMPOUNDS DISSOLVED IN A FLUORINATED SOLVENT, AND USE THEREOF FOR COVERING THE SURFACE OF A PART

Surfactis Technologies, ...

1. A liquid composition containing at least one bisphosphonic compound bearing at least one partially fluorinated, perfluorinated (PF) or perfluoropolyether (PFPE) group, wherein said bisphosphonic compound is dissolved in a nonflammable fluorinated solvent or in a mixture of nonflammable fluorinated solvents.
US Pat. No. 10,556,014

COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT

ELLIPSES PHARMA LIMITED, ...

1. A compound or pharmaceutically acceptable salt thereof, comprising a compound X which promotes the formation of stable microtubules in a manner similar to paclitaxel associated with a peptide Y comprising a matrix metalloproteinase cleavage site comprising the amino acid sequence -Arg-Ser-Cit-Gly-Hof-Tyr-Leu- (SEQ ID NO: 4).
US Pat. No. 10,557,040

ANTI-CORROSION COATINGS LOADED WITH MESOSTRUCTURED PARTICLES

AIRBUS, Blagnac (FR)

1. A coating comprising at least one layer comprising individual and mesostructured spherical micrometric particles, said mesostructured spherical micrometric particles being loaded with at least one element selected from among functional corrosion-inhibiting molecules and functional corrosion-inhibiting nano-objects and formed by a continuous non-dissociable nebulization of a liquid solution at a predetermined molar concentration in a solvent to obtain a fog of solution droplets and heating the fog solution droplets to evaporate the solvent and volatile compounds in a single reactor, the liquid solution comprising one or more precursors from a three-dimensional network of particles and said at least one element chosen from the functional corrosion-inhibiting molecules and the functional corrosion-inhibiting nano-objects; and wherein said at least one layer is a sealed hybrid organic-inorganic layer, containing a sol-gel or sealed primer layer, that is closed and sealed to limit penetration of corrosive materials.
US Pat. No. 10,556,015

LYSOSOMAL TARGETING OF ENZYMES, AND USES THEREOF

Criteo S.A., Paris (FR)

1. A targeted therapeutic fusion protein comprising a lysosomal enzyme fused to a lysosomal targeting moiety comprising a proprotein convertase subtilisin kexin type 9 (PCSK9) protein comprising amino acid substitutions S386A and F379A.
US Pat. No. 10,557,041

ANTI-CORROSION COMPOSITION COMPRISING POLYISOBUTYLENES

1. Anti-corrosion composition comprising:at least a first polyisobutylene with a Staudinger index J0 ranging from about 15 cm3/g to about 98 cm3/g and an average relative molar mass Mv ranging from about 32,000 g/mol to about 280,000 g/mol and at least a second polyisobutylene with a Staudinger index J0 ranging from about 105 cm3/g to about 238 cm3/g and an average relative molar mass Mv ranging from about 350,000 g/mol to about 900,000 g/mol and at least a third polyisobutylene with a Staudinger index J0 ranging from about 240 cm3/g to about 900 cm3/g and an average relative molar mass Mv ranging from about 950,000 g/mol to about 5,500,000 g/mol.
US Pat. No. 10,556,016

ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR PRODUCING AND USING THE SAME

Indiana University Resear...

1. A biomimetic Janus particle comprising:a) a particle;
b) at least one substantially concentric pattern of a first ligand population bound to the particle, wherein the first ligand population comprises one or more ligands involved in T cell activation and/or one or more molecules to which a ligand involved in T cell activation may be bound; and
c) a second ligand population bound to the particle, wherein the second ligand population is different than the first ligand population and does not substantially overlap the substantially concentric pattern of the first ligand population, and wherein the second ligand population comprises one or more ligands involved in T cell activation and/or one or more molecules to which a ligand involved in T cell activation may be bound,
wherein one of the first ligand population or second ligand population comprise an integrin-binding ligand.
US Pat. No. 10,557,042

SLIPPERY LIQUID-INFUSED POROUS SURFACES THAT PREVENT MICROBIAL SURFACE FOULING

Wisconsin Alumni Research...

1. A slippery liquid-infused porous surface (SLIPS) that controllably releases a molecule, wherein said slippery oil-infused surface comprises:a) a porous matrix having nanoscale or microscale porosity;
b) an oil covering at least a portion of the porous matrix, wherein said oil at least partially fills the pores of the porous matrix; and
c) one or more small-molecule compounds, wherein the one or more small-molecule compounds are located on the surface or in said porous matrix, within said oil, or both,
wherein the slippery oil-infused surface is able to controllably release the one or more small-molecule compounds when the slippery oil-infused surface is immersed into media.
US Pat. No. 10,557,043

TEMPERATURE-SENSITIVE NANO SILVER CONTROLLED-RELEASE SMART ANTIBACTERIAL COATING AND PREPARATION METHOD THEREFOR

FU ZHOU UNIVERSIT, Fuzho...

1. A temperature-sensitive nano-silver controlled release antibacterial coating composite comprising:25˜35 parts by weight of water,
30˜40 parts by weight of acrylic,
20˜30 parts by weight of polyurethane resin,
2˜3 parts by weight of temperature-sensitive nano-silver controlled release antibacterial agent,
1.5˜2.5 parts by weight of dispersant,
1.0˜1.5 parts by weight of curing agent,
0.8˜1.0 parts by weight of defoamer,
0.5˜0.8 parts by weight of filming additive, and
0.5˜0.8 parts by weight of leveling agent;
wherein the temperature-sensitive nano-silver controlled release antibacterial agent is nano-silver adsorbed to particles of nanometer mesoporous SiO2 modified by poly N-isopropyl acrylamide;
above 32° C. poly N-isopropyl acrylamide on the surface of nano-mesoporous SiO2 particles will shrink, blocking the mesopores and thus preventing the release of internal nano-Ag: when the temperature is below 32° C. poly N-isopropyl acrylamide on the surface of nano-mesoporous SiO2 particles will be in the dilated state, the release of internal nano-Ag becomes unimpeded, so that controlled release of nano Ag can be achieved.
US Pat. No. 10,555,506

NON-HUMAN MAMMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES

ABLEXIS, LLC, San Diego,...

1. A mouse whose genome comprises a transgene comprising an immunoglobulin heavy chain (IgH) locus, or a portion thereof, wherein said IgH locus comprises in operable linkage from 5? to 3? an unrearranged DNA sequence of a human variable heavy (VH) gene segment, a diversity heavy (DH) gene segment, and a human joining heavy (JH) gene segment, operably linked to a constant region gene comprising a human CH1 exon, a human Cupper hinge exon, a human or mouse Cmiddle hinge exon, a mouse CH2 exon and a mouse CH3 exon, wherein the human CH1 exon is selected from the group consisting of a human mu constant region (C?) CH1 exon, a human delta constant region (C?) CH1 exon, a human gamma-1 constant region (C?l) CH1 exon, a human gamma-2 constant region (C?2) CH1 exon, a human gamma-4 constant region (C?4) CH1 exon, a human alpha constant region (C?) CH1 exon, and a human epsilon constant region (C?) CH1 exon, wherein the IgH locus further comprise an IgH non-coding region and wherein during B cell development, the IgH locus undergoes gene rearrangement and expresses a chimeric immunoglobulin heavy chain comprising a human heavy chain variable domain and a chimeric IgH constant domain.
US Pat. No. 10,555,507

NON-HUMAN ANIMALS HAVING HUMANIZED FC-GAMMA RECEPTORS

Regeneron Pharmaceuticals...

1. A mouse whose genome comprises an Fc?RI gene at an endogenous Fc?RI locus, wherein the Fc?RI gene encodes a functional Fc?RI protein comprising an extracellular portion of a human Fc?RI ? chain and an intracellular portion of a mouse Fc?RI ? chain, wherein the mouse expresses the functional Fc?RI protein encoded by the Fc?RI gene.
US Pat. No. 10,556,019

HUMAN MICRORNAS FOR TREATMENT OF MALIGNANT TUMOURS

1. A method of treatment of breast cancer, comprising:administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule consisting essentially of a sequence selected from the group consisting of SEQ ID NO 001 and SEQ ID NO 002,wherein the nucleic acid molecule initiates apoptosis in cancerous cells, thereby treating the breast cancer.
US Pat. No. 10,557,045

PIGMENT DISPERSANT WITH HINDERED LIGHT AMINE STABILIZER AND PIGMENT DISPERSIONS AND COATING COMPOSITIONS BASED THEREON

PPG Industries Ohio, Inc....

1. A pigment dispersion comprising (a) at least one pigment and (b) a polymeric dispersant comprising residual units derived from polymerization of a mixture of monomers comprising (b1) at least one ethylenically unsaturated hindered amine light stabilizing monomer and (b2) at least one additional ethylenically unsaturated monomer different from monomer (b1),wherein the polymeric dispersant further comprises at least one linkage in the polymer selected from an ester linkage, an ether linkage or a combination thereof.
US Pat. No. 10,555,508

IN VIVO METHOD FOR GENERATING DIVERSITY IN A PROTEIN SCAFFOLD

CRYSTAL BIOSCIENCE INC., ...

1. A transgenic chicken comprising a genome comprising an immunoglobulin heavy chain locus comprising:(a) a transcribed gene encoding a fusion protein comprising, from N-terminus to C-terminus: a binding domain from a heavy chain-only antibody and, operably linked to said binding domain, at least part of a heavy chain constant region that is native to said transgenic chicken; and
(b) a plurality of pseudogenes that are operably linked to said transcribed gene and that donate, by gene conversion, nucleotide sequence to the part of said transcribed gene that encodes said binding domain, wherein the pseudogenes are upstream or downstream of the transcribed gene and contain a nucleotide sequence that is at least 80% identical to at least part of the transcribed gene;
wherein the genome of the chicken further comprises an immunoglobulin light chain locus that encodes a light chain constant region but not a light chain variable domain, and
wherein the transgenic chicken produces a diversified population of antibodies whose binding specificity is solely determined by a diversified binding domain of (a).
US Pat. No. 10,556,020

RNA-MODULATING AGENTS

UNIVERSITY OF MASSACHUSET...

1. An RNA-modulating agent comprising an mRNA binding sequence that is complementary to a portion of a target mRNA sequence, linked to two or more miRNA binding sequences, wherein one or more of the miRNA binding sequences are complementary to positions 2 to 8, and 12 to 15, 12 to 16, or 12 to 17 of the miRNA, but not complementary to positions 1, 10 and 11 of the miRNA.
US Pat. No. 10,556,022

IMAGEABLE POLYMERS

Biocompatibles UK Ltd., ...

1. Hydrogel polymer microspheres wherein the hydrogel polymer comprises: a polyvinyl alcohol (PVA) backbone comprising at least two pendant chains having cross-linkable ethylenically unsaturated functional groups which are cross linked by a vinylic co-monomer;wherein the PVA comprising 1,3 diol groups is acetalised with a radiopaque species which is coupled to the hydrogel polymer through a cyclic acetal group, the radiopaque species comprising one or more covalently bound iodines.
US Pat. No. 10,557,048

INKS

Fujifilm Imaging Colorant...

1. An ink comprising:(a) from 0.5 to 5 parts of a self-dispersible pigment;
(b) from 5 to 8 parts of a styrene acrylic latex binder;
(c) from 0 to 5 parts of a glycol selected from the group consisting of ethylene glycol, diethylene glycol, propylene glycol, dipropylene glycol or triethylene glycol;
(d) from 1 to 10 parts of 2-pyrrolidone;
(e) from 1 to 15 parts of glycerol;
(f) from 0.1 to 0.5 parts of 2,4,7,9-tetramethyl-5-decyne-4,7-diol or an ethylene oxide condensate thereof;
(g) from 0.001 to 5 parts of biocide;
(h) from 0 to 10 parts of a polyethylene glycol; and
(i) the balance to 100 parts water, wherein the ink has a surface tension of from 30 to 40 dynes/cm when measured at 25° C. using a Kruss K100 tensiometer.
US Pat. No. 10,556,024

18F LABELING OF PROTEINS USING SORTASES

Whitehead Institute for B...

1. A method for labeling a protein having a sortase recognition motif comprising:contacting the protein with a sortase substrate peptide in the presence of a sortase to transamidate the protein and the sortase substrate peptide, wherein the sortase substrate peptide comprises a click chemistry handle; and
contacting the protein with a radiolabeled agent, wherein the radiolabeled agent comprises a click chemistry handle which reacts with the click chemistry handle of the protein, thereby producing a radiolabeled protein,
wherein the radiolabeled agent comprises fluorodeoxyglucose (18F-FDG), and wherein the click chemistry handle is linked to the fluorodeoxyglucose via an oxime linkage;
wherein the protein comprises a C-terminal sortase recognition motif LPXTG or NPXTX, wherein each instance of X independently represents any amino acid residue, and the sortase substrate peptide comprises a N-terminal sortase recognition motif oligoglycine or oligoalanine;
wherein the sortase substrate peptide is linked to the radiolabeled agent by an oxime linkage, a hydrazone linkage, a thiosemicarbazone linkage, a heterocyclylene linkage, an amide linkage, an ester linkage, an ether linkage, or a disulfide linkage.
US Pat. No. 10,557,818

CEPHALOPOD PROTEINS AS PROTON CONDUCTORS

The Regents of the Univer...

1. A protonic transistor, comprisinga source electrode;
a drain electrode;
a protonic channel structure comprising a cephalopod proton-conducting protein comprising SEQ ID NO: 1 and/or a reflectin; and
a gate electrode in contact with or in proximity to the protonic channel structure.
US Pat. No. 10,557,051

METHOD FOR PRODUCING AN INK, INK, AND USE OF SAME

FORSCHUNGSZENTRUM JUELICH...

1. A method for producing an ink, comprising:a) producing, via a wet milling process using a first solvent, nanoparticles having a size of 0.1 to 20 nm;
b) covalently bonding, by coupling reactions, short-chain, branched organic stabilizer molecules to surfaces of the nanoparticles to form stabilized nanoparticles; and
c) forming the ink by dissolving the stabilized nanoparticles in a second solvent and dispersing the stabilized nanoparticles in the second solvent.
US Pat. No. 10,557,053

UNIVERSAL PIGMENT PREPARATIONS FOR POINT-OF-SALE USE

BASF SE, Ludwigshafen (D...

1. A pigment preparation comprising, based in each case on the total weight of the preparation,(A) 1 to 80 wt % of a pigment component which comprises a pigment and optionally a filler;
(B) 0.01 to 10 wt % of a water-soluble, anionic, surface-active additive selected from the group consisting of homo- and copolymers of ethylenically unsaturated monocarboxylic acids and/or ethylenically unsaturated dicarboxylic acids, which may further comprise, in copolymerized form, vinyl monomers comprising no acid function, and of the salts of the homo- and copolymers, the homo- and copolymers being at least partly esterified with a polyether alcohol or a derivative thereof;
(C) 0.01 to 8 wt % of a phosphoric ester of the formula (I):
[RO—(C2-C3-alkylene oxide)y]x-PO(OH)3-x  (I)
wherein
the radical R independently at each occurrence is linear or branched C8-C22-alkyl, C8-C22-alkenyl or phenyl which may be substituted by C1-C12-alkyl, styryl or methyl-substituted styryl,
the (C2-C3-alkylene oxide) group is ethylene oxide and/or propylene oxide,
x=1 or 2, and
y=1-100;
(D) 0 to 20 wt % of one or more further additives customary for aqueous pigment preparations; and
(E) water,
where the sum of the percentages by weight of components (A) to (E) makes 100 wt %.
US Pat. No. 10,556,798

SYNTHESIS OF FLUORINATED GRAPHENE OXIDE FOR ELECTROCHEMICAL APPLICATIONS

LAKEHEAD UNIVERSITY, Thu...

1. A method for synthesis of about 0.5 to about 1.5 at. % fluorinated grapheme oxide comprising:mixing about n grams of graphite with about 5*n to about 40*n ml HF in a solution of about 50*n to about 150*n ml of H2SO4/H3PO4 at a ratio of 10-x:x, where x=0.1 to 4 with stirring at a temperature of about 30 to about 80° C. for a first period of time to generate a first mixture;
adding about 3*n to about 10*n g KMnO4 to the first mixture to generate a second mixture and stirring the second mixture at a temperature of about 40 to about 80° C. for a second period of time;
adding the second mixture to a container containing about 50*n to about 250*n ml of ice and about 1*n to about 10*n ml of H2O2 to generate a third mixture;
separating solid comprising about 0.5 to about 1.5 at. % fluorinated grapheme oxide from the third mixture;
rinsing the fluorinated graphene oxide; and
drying the fluorinated graphene oxide.
US Pat. No. 10,556,799

TRITERTBUTYL ALUMINUM REACTANTS FOR VAPOR DEPOSITION

ASM IP HOLDING B.V., Alm...

1. A deposition reactor comprising a first reactant container fluidly connected to a reaction chamber, the reactant container comprising a first precursor composition comprising at least 50% Isomer 1, at least 50% Isomer 2, or at least 20% of a combination of Isomer 1 and Isomer 2 of Al(tert-Bu)3, wherein Isomer 1 has the formula Al(tert-Bu)2(iso-Bu) and Isomer 2 has the formula Al(tert-Bu)(iso-Bu)2.